Details of the Drug Combinations

General Information of This Drug (ID: DM3BH1Y)

Drug Name
Lapatinib   DM3BH1Y
Synonyms
FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [1]
Gastroesophageal junction adenocarcinoma 2B71 Approved [2]
Melanoma 2C30 Approved [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1316 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABIRATERONE + Lapatinib DCCW3EN ABIRATERONE Invasive ductal carcinoma (Cell Line: BT-549) [3]
ABIRATERONE + Lapatinib DCD936W ABIRATERONE Melanoma (Cell Line: SK-MEL-2) [4]
ABIRATERONE + Lapatinib DCW2DD3 ABIRATERONE Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Amonafide + Lapatinib DCJHT1L Amonafide Adenocarcinoma (Cell Line: DU-145) [5]
Amonafide + Lapatinib DCOU3Y5 Amonafide Adenocarcinoma (Cell Line: A549) [5]
Amonafide + Lapatinib DCTYQ8W Amonafide Adenocarcinoma (Cell Line: HCT-15) [5]
Amonafide + Lapatinib DCVU924 Amonafide Adenocarcinoma (Cell Line: HCC-2998) [5]
Amonafide + Lapatinib DC5D830 Amonafide Anaplastic large cell lymphoma (Cell Line: SR) [5]
Amonafide + Lapatinib DC1DJU9 Amonafide Astrocytoma (Cell Line: SNB-19) [5]
Amonafide + Lapatinib DC6QN22 Amonafide Clear cell renal cell carcinoma (Cell Line: A498) [5]
Amonafide + Lapatinib DCN5W34 Amonafide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Amonafide + Lapatinib DCTAEH4 Amonafide Lung adenocarcinoma (Cell Line: EKVX) [5]
Amonafide + Lapatinib DC9TBUN Amonafide Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Anastrozole + Lapatinib DC5NFOY Anastrozole Adenocarcinoma (Cell Line: DU-145) [5]
Anastrozole + Lapatinib DCIPCNR Anastrozole Adenocarcinoma (Cell Line: A549) [5]
Anastrozole + Lapatinib DCBFTCX Anastrozole Adenocarcinoma (Cell Line: HT29) [5]
Anastrozole + Lapatinib DCMEEVM Anastrozole Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Anastrozole + Lapatinib DC0U2PK Anastrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Anastrozole + Lapatinib DCZFM12 Anastrozole Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Anastrozole + Lapatinib DCKHEPY Anastrozole Amelanotic melanoma (Cell Line: M14) [5]
Anastrozole + Lapatinib DCDT5GF Anastrozole Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Anastrozole + Lapatinib DCPNM6K Anastrozole Glioma (Cell Line: SF-295) [5]
Anastrozole + Lapatinib DCKA679 Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Anastrozole + Lapatinib DCPDTOB Anastrozole Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Anastrozole + Lapatinib DCTJ047 Anastrozole Malignant melanoma (Cell Line: LOX IMVI) [5]
Anastrozole + Lapatinib DCDJOAL Anastrozole Malignant melanoma (Cell Line: UACC62) [5]
Anastrozole + Lapatinib DCDAL0F Anastrozole Melanoma (Cell Line: UACC-257) [5]
Anastrozole + Lapatinib DCW5339 Anastrozole Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Anastrozole + Lapatinib DC098K3 Anastrozole Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Anastrozole + Lapatinib DCEZJFV Anastrozole Colon adenocarcinoma (Cell Line: COLO 205) [3]
Anastrozole + Lapatinib DC4PXPN Anastrozole Invasive ductal carcinoma (Cell Line: BT-549) [3]
Arfolitixorin + Lapatinib DCX3AP6 Arfolitixorin Astrocytoma (Cell Line: SNB-19) [5]
Arfolitixorin + Lapatinib DC49AOR Arfolitixorin Glioma (Cell Line: SF-295) [5]
Arfolitixorin + Lapatinib DCB3610 Arfolitixorin Carcinoma (Cell Line: MCF7) [3]
Arfolitixorin + Lapatinib DCSFGNA Arfolitixorin Adenocarcinoma (Cell Line: HCT116) [4]
Azacitidine + Lapatinib DCGXNIU Azacitidine Anaplastic large cell lymphoma (Cell Line: SR) [5]
BIO-300 + Lapatinib DCVY6WE BIO-300 Anaplastic large cell lymphoma (Cell Line: SR) [5]
BIO-300 + Lapatinib DCD226Z BIO-300 Glioblastoma (Cell Line: SNB-75) [5]
BIO-300 + Lapatinib DCC1MKW BIO-300 Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
BIO-300 + Lapatinib DCRTCWK BIO-300 Carcinoma (Cell Line: MCF7) [3]
BIO-300 + Lapatinib DCNJEOO BIO-300 Adenocarcinoma (Cell Line: DU-145) [4]
BIO-300 + Lapatinib DCCO1N2 BIO-300 Adenocarcinoma (Cell Line: OVCAR3) [4]
BIO-300 + Lapatinib DCK8ZIQ BIO-300 Adenocarcinoma (Cell Line: A549) [4]
BIO-300 + Lapatinib DC2X8X2 BIO-300 Adenocarcinoma (Cell Line: HCT-15) [4]
BIO-300 + Lapatinib DCF4HT3 BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
BIO-300 + Lapatinib DCCTYAE BIO-300 Lung adenocarcinoma (Cell Line: EKVX) [4]
BIO-300 + Lapatinib DCF7I4X BIO-300 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
BIO-300 + Lapatinib DC2VFDK BIO-300 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
BIO-300 + Lapatinib DCJ61CR BIO-300 Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Bleomycin + Lapatinib DCMAUFX Bleomycin Anaplastic large cell lymphoma (Cell Line: SR) [5]
Bleomycin + Lapatinib DC956JE Bleomycin Astrocytoma (Cell Line: SNB-19) [5]
Bleomycin + Lapatinib DC72L5X Bleomycin Adenocarcinoma (Cell Line: A549) [4]
Bleomycin + Lapatinib DCQYRVM Bleomycin Adenocarcinoma (Cell Line: HCT-15) [4]
Bleomycin + Lapatinib DCYLN1L Bleomycin Lung adenocarcinoma (Cell Line: EKVX) [4]
Bleomycin + Lapatinib DCV69QH Bleomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Cabazitaxel + Lapatinib DCTDX8U Cabazitaxel Adenocarcinoma (Cell Line: DU-145) [5]
Cabazitaxel + Lapatinib DC5UDAO Cabazitaxel Adenocarcinoma (Cell Line: OVCAR3) [5]
Cabazitaxel + Lapatinib DCSWUFZ Cabazitaxel Adenocarcinoma (Cell Line: HCT-15) [5]
Cabazitaxel + Lapatinib DC6EHCP Cabazitaxel Anaplastic large cell lymphoma (Cell Line: SR) [5]
Cabazitaxel + Lapatinib DCGN32T Cabazitaxel Chronic myelogenous leukemia (Cell Line: K-562) [5]
Cabazitaxel + Lapatinib DCECAA8 Cabazitaxel Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Cabazitaxel + Lapatinib DCPME1X Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Cabazitaxel + Lapatinib DCRRBHJ Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Cabazitaxel + Lapatinib DCY944Q Cabazitaxel Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Cabazitaxel + Lapatinib DC3849A Cabazitaxel Lung adenocarcinoma (Cell Line: EKVX) [5]
Cabazitaxel + Lapatinib DCQ0XX1 Cabazitaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Cabazitaxel + Lapatinib DCU1XW9 Cabazitaxel Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Cabazitaxel + Lapatinib DC114U1 Cabazitaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Lapatinib DCO6T67 Crizotinib Astrocytoma (Cell Line: U251) [5]
Crizotinib + Lapatinib DCO2IS8 Crizotinib Chronic myelogenous leukemia (Cell Line: K-562) [5]
Crizotinib + Lapatinib DCNGCN0 Crizotinib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Crizotinib + Lapatinib DCV0NB6 Crizotinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Cyclophosphamide + Lapatinib DCGSNI4 Cyclophosphamide Germ cell tumour (Cell Line: PA1) [5]
Cyclophosphamide + Lapatinib DCG6AF4 Cyclophosphamide Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Cyclophosphamide + Lapatinib DCCILOS Cyclophosphamide Malignant melanoma (Cell Line: A375) [5]
Dacarbazine + Lapatinib DCONUCV Dacarbazine Adenocarcinoma (Cell Line: NCIH23) [5]
Dacarbazine + Lapatinib DCBPCIF Dacarbazine Adenocarcinoma (Cell Line: SW-620) [5]
Dacarbazine + Lapatinib DC5MQGC Dacarbazine Adenocarcinoma (Cell Line: HCT-15) [5]
Dacarbazine + Lapatinib DCHOMR9 Dacarbazine Adenocarcinoma (Cell Line: HCT116) [5]
Dacarbazine + Lapatinib DCVTWBH Dacarbazine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Dacarbazine + Lapatinib DCV47KL Dacarbazine Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Dacarbazine + Lapatinib DC7GYHU Dacarbazine Amelanotic melanoma (Cell Line: M14) [5]
Dacarbazine + Lapatinib DC5ZLYQ Dacarbazine Anaplastic large cell lymphoma (Cell Line: SR) [5]
Dacarbazine + Lapatinib DCBZ75X Dacarbazine Astrocytoma (Cell Line: SNB-19) [5]
Dacarbazine + Lapatinib DCOHM0D Dacarbazine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Dacarbazine + Lapatinib DCPYPW4 Dacarbazine Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Dacarbazine + Lapatinib DCBFCH4 Dacarbazine Glioma (Cell Line: SF-295) [5]
Dacarbazine + Lapatinib DCVBYCQ Dacarbazine Glioma (Cell Line: SF-268) [5]
Dacarbazine + Lapatinib DCQKYJG Dacarbazine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Dacarbazine + Lapatinib DCYBKQM Dacarbazine Lung adenocarcinoma (Cell Line: HOP-62) [5]
Dacarbazine + Lapatinib DCHD6O8 Dacarbazine Malignant melanoma (Cell Line: LOX IMVI) [5]
Dacarbazine + Lapatinib DCVAKD7 Dacarbazine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Dactinomycin + Lapatinib DCEGI6A Dactinomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Dactinomycin + Lapatinib DC72B95 Dactinomycin Carcinoma (Cell Line: MCF7) [3]
Dactinomycin + Lapatinib DCN7ZQY Dactinomycin Colon carcinoma (Cell Line: KM12) [3]
Dactinomycin + Lapatinib DC3VS3A Dactinomycin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Dactinomycin + Lapatinib DCB3QBD Dactinomycin Invasive ductal carcinoma (Cell Line: T-47D) [3]
Dactinomycin + Lapatinib DCY0WYS Dactinomycin Adenocarcinoma (Cell Line: DU-145) [4]
Dactinomycin + Lapatinib DC2GC4U Dactinomycin Adenocarcinoma (Cell Line: OVCAR3) [4]
Dactinomycin + Lapatinib DCRUBNY Dactinomycin Adenocarcinoma (Cell Line: A549) [4]
Dactinomycin + Lapatinib DC01KB0 Dactinomycin Adenocarcinoma (Cell Line: NCIH23) [4]
Dactinomycin + Lapatinib DC5UK6I Dactinomycin Adenocarcinoma (Cell Line: HT29) [4]
Dactinomycin + Lapatinib DCVOYJ1 Dactinomycin Adenocarcinoma (Cell Line: HCT116) [4]
Dactinomycin + Lapatinib DCLRBC3 Dactinomycin Adenocarcinoma (Cell Line: HCC-2998) [4]
Dactinomycin + Lapatinib DCFSJU5 Dactinomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Dactinomycin + Lapatinib DCHHRYC Dactinomycin Amelanotic melanoma (Cell Line: M14) [4]
Dactinomycin + Lapatinib DC0I8RR Dactinomycin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Dactinomycin + Lapatinib DC5QKTX Dactinomycin Astrocytoma (Cell Line: SNB-19) [4]
Dactinomycin + Lapatinib DC53MRX Dactinomycin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Dactinomycin + Lapatinib DCUWY3F Dactinomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Dactinomycin + Lapatinib DC18LJG Dactinomycin Clear cell renal cell carcinoma (Cell Line: A498) [4]
Dactinomycin + Lapatinib DCVAOTO Dactinomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Dactinomycin + Lapatinib DCYVNN4 Dactinomycin Glioblastoma (Cell Line: SNB-75) [4]
Dactinomycin + Lapatinib DC30J9C Dactinomycin Glioma (Cell Line: SF-539) [4]
Dactinomycin + Lapatinib DCWGTB4 Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Dactinomycin + Lapatinib DCBBQES Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Dactinomycin + Lapatinib DCHPYAH Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Dactinomycin + Lapatinib DCTBK26 Dactinomycin Lung adenocarcinoma (Cell Line: HOP-62) [4]
Dactinomycin + Lapatinib DCRW0DN Dactinomycin Lung adenocarcinoma (Cell Line: EKVX) [4]
Dactinomycin + Lapatinib DCRWWHI Dactinomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Dactinomycin + Lapatinib DCP9HY3 Dactinomycin Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Dactinomycin + Lapatinib DCCGWYK Dactinomycin Malignant melanoma (Cell Line: UACC62) [4]
Dactinomycin + Lapatinib DCJA8U8 Dactinomycin Malignant melanoma (Cell Line: LOX IMVI) [4]
Dactinomycin + Lapatinib DCF1S8Z Dactinomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Dactinomycin + Lapatinib DC941RD Dactinomycin Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Dactinomycin + Lapatinib DCNO2GN Dactinomycin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Dactinomycin + Lapatinib DCW7SEY Dactinomycin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Dactinomycin + Lapatinib DC9XRW4 Dactinomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Dactinomycin + Lapatinib DCSTMDQ Dactinomycin Renal cell carcinoma (Cell Line: SN12C) [4]
Dactinomycin + Lapatinib DCB6EQB Dactinomycin Renal cell carcinoma (Cell Line: UO-31) [4]
Dasatinib + Lapatinib DCPOG9C Dasatinib Adenocarcinoma (Cell Line: OVCAR3) [5]
Dasatinib + Lapatinib DCXGD6U Dasatinib Adenocarcinoma (Cell Line: HT29) [5]
Dasatinib + Lapatinib DCA86OR Dasatinib Adenocarcinoma (Cell Line: HCT-15) [5]
Dasatinib + Lapatinib DC7CHFV Dasatinib Astrocytoma (Cell Line: SNB-19) [5]
Dasatinib + Lapatinib DCHVRP5 Dasatinib Glioma (Cell Line: SF-539) [5]
Dasatinib + Lapatinib DCAFJY9 Dasatinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Dasatinib + Lapatinib DC0KQEI Dasatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Dasatinib + Lapatinib DCY4TSW Dasatinib Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Dasatinib + Lapatinib DCF98BX Dasatinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Dasatinib + Lapatinib DCQMI9N Dasatinib Carcinoma (Cell Line: RXF 393) [3]
Dasatinib + Lapatinib DCF80D1 Dasatinib Carcinoma (Cell Line: MCF7) [3]
Dexamethasone + Lapatinib DC6HX86 Dexamethasone Colon adenocarcinoma (Cell Line: LOVO) [3]
Dexamethasone + Lapatinib DCXESMF Dexamethasone Adenocarcinoma (Cell Line: CAOV3) [4]
Dexamethasone + Lapatinib DCPU7Z8 Dexamethasone Adenocarcinoma (Cell Line: OVCAR3) [4]
Dexamethasone + Lapatinib DCQ5G9N Dexamethasone Adenocarcinoma (Cell Line: NCIH1650) [4]
Dexamethasone + Lapatinib DCVPVB3 Dexamethasone Adenocarcinoma (Cell Line: NCIH2122) [4]
Dexamethasone + Lapatinib DCR46IZ Dexamethasone Adenocarcinoma (Cell Line: NCIH520) [4]
Dexamethasone + Lapatinib DCVSEVB Dexamethasone Adenocarcinoma (Cell Line: SW-620) [4]
Dexamethasone + Lapatinib DC87ZNB Dexamethasone Germ cell tumour (Cell Line: PA1) [4]
Dexamethasone + Lapatinib DCJ9ULG Dexamethasone Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Dexrazoxane + Lapatinib DCS4CV5 Dexrazoxane Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Dexrazoxane + Lapatinib DCBJZ4P Dexrazoxane Anaplastic large cell lymphoma (Cell Line: SR) [5]
Dexrazoxane + Lapatinib DCCUOVY Dexrazoxane Adenocarcinoma (Cell Line: A549) [4]
Dexrazoxane + Lapatinib DCI3I53 Dexrazoxane Adenocarcinoma (Cell Line: HCT116) [4]
Dexrazoxane + Lapatinib DC4GDII Dexrazoxane Adenocarcinoma (Cell Line: HT29) [4]
DFN-15 + Lapatinib DC4QU8V DFN-15 Anaplastic large cell lymphoma (Cell Line: SR) [5]
DFN-15 + Lapatinib DC5CNFZ DFN-15 Glioma (Cell Line: SF-268) [5]
DFN-15 + Lapatinib DCZHX99 DFN-15 Malignant melanoma (Cell Line: LOX IMVI) [4]
Digitoxin + Lapatinib DCFXT0Q Digitoxin Clear cell renal cell carcinoma (Cell Line: A498) [5]
Digitoxin + Lapatinib DCWPU0E Digitoxin Glioma (Cell Line: SF-295) [5]
Docetaxel + Lapatinib DC4VBJV Docetaxel Adenocarcinoma (Cell Line: DU-145) [5]
Docetaxel + Lapatinib DCHM8YK Docetaxel Adenocarcinoma (Cell Line: OVCAR3) [5]
Docetaxel + Lapatinib DCQFXNS Docetaxel Adenocarcinoma (Cell Line: NCIH23) [5]
Docetaxel + Lapatinib DC0OOEX Docetaxel Adenocarcinoma (Cell Line: A549) [5]
Docetaxel + Lapatinib DCQ82XX Docetaxel Adenocarcinoma (Cell Line: HT29) [5]
Docetaxel + Lapatinib DCU75ES Docetaxel Adenocarcinoma (Cell Line: SW-620) [5]
Docetaxel + Lapatinib DCVZJK5 Docetaxel Adenocarcinoma (Cell Line: HCC-2998) [5]
Docetaxel + Lapatinib DCJYPDC Docetaxel Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Docetaxel + Lapatinib DCJ2DRU Docetaxel Anaplastic large cell lymphoma (Cell Line: SR) [5]
Docetaxel + Lapatinib DCG0H0W Docetaxel Astrocytoma (Cell Line: U251) [5]
Docetaxel + Lapatinib DC3SG1L Docetaxel Astrocytoma (Cell Line: SNB-19) [5]
Docetaxel + Lapatinib DCD71JE Docetaxel Chronic myelogenous leukemia (Cell Line: K-562) [5]
Docetaxel + Lapatinib DCIDU6D Docetaxel Clear cell renal cell carcinoma (Cell Line: A498) [5]
Docetaxel + Lapatinib DCLGGE5 Docetaxel Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Docetaxel + Lapatinib DCVRS9R Docetaxel Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Docetaxel + Lapatinib DCVYS4Y Docetaxel Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Docetaxel + Lapatinib DCJUS37 Docetaxel Glioblastoma (Cell Line: SNB-75) [5]
Docetaxel + Lapatinib DCUNV1Y Docetaxel Glioma (Cell Line: SF-539) [5]
Docetaxel + Lapatinib DC39VSH Docetaxel Glioma (Cell Line: SF-295) [5]
Docetaxel + Lapatinib DCCJ31K Docetaxel Glioma (Cell Line: SF-268) [5]
Docetaxel + Lapatinib DCZR14Y Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Docetaxel + Lapatinib DCVSL3V Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Docetaxel + Lapatinib DCHG9QR Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Docetaxel + Lapatinib DCTN7WO Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Docetaxel + Lapatinib DCQMRVP Docetaxel Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Docetaxel + Lapatinib DC99A6Q Docetaxel Lung adenocarcinoma (Cell Line: HOP-62) [5]
Docetaxel + Lapatinib DC7LUF1 Docetaxel Lung adenocarcinoma (Cell Line: EKVX) [5]
Docetaxel + Lapatinib DCUQLAC Docetaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Docetaxel + Lapatinib DCQORSE Docetaxel Malignant melanoma (Cell Line: UACC62) [5]
Docetaxel + Lapatinib DCKQFFA Docetaxel Malignant melanoma (Cell Line: LOX IMVI) [5]
Docetaxel + Lapatinib DCN5A0C Docetaxel Melanoma (Cell Line: MALME-3M) [5]
Docetaxel + Lapatinib DC9LZY9 Docetaxel Melanoma (Cell Line: UACC-257) [5]
Docetaxel + Lapatinib DCS5KHY Docetaxel Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Docetaxel + Lapatinib DCEKZ3B Docetaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Docetaxel + Lapatinib DC2T3LE Docetaxel Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Docetaxel + Lapatinib DC4E33P Docetaxel Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Docetaxel + Lapatinib DCDWB06 Docetaxel Prostate carcinoma (Cell Line: PC-3) [5]
Docetaxel + Lapatinib DC4DNP0 Docetaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Docetaxel + Lapatinib DCRWPMI Docetaxel Carcinoma (Cell Line: RXF 393) [3]
Docetaxel + Lapatinib DC9IQZD Docetaxel Carcinoma (Cell Line: MCF7) [3]
Docetaxel + Lapatinib DCOD7JZ Docetaxel Colon adenocarcinoma (Cell Line: COLO 205) [3]
Docetaxel + Lapatinib DCX0WP7 Docetaxel Colon carcinoma (Cell Line: KM12) [3]
Docetaxel + Lapatinib DCI9H2I Docetaxel Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Docetaxel + Lapatinib DCUJ54V Docetaxel Invasive ductal carcinoma (Cell Line: BT-549) [3]
Docetaxel + Lapatinib DCSIW26 Docetaxel Invasive ductal carcinoma (Cell Line: T-47D) [3]
Doxorubicin + Lapatinib DCO1WJY Doxorubicin Adenocarcinoma (Cell Line: CAOV3) [5]
Doxorubicin + Lapatinib DCGCV4L Doxorubicin Adenocarcinoma (Cell Line: A427) [5]
Doxorubicin + Lapatinib DCLJEWA Doxorubicin Adenocarcinoma (Cell Line: NCIH1650) [5]
Doxorubicin + Lapatinib DCI024N Doxorubicin Adenocarcinoma (Cell Line: NCIH2122) [5]
Doxorubicin + Lapatinib DC4JK9Q Doxorubicin Adenocarcinoma (Cell Line: NCIH23) [5]
Doxorubicin + Lapatinib DCLS5DD Doxorubicin Adenocarcinoma (Cell Line: COLO320DM) [5]
Doxorubicin + Lapatinib DCVDI72 Doxorubicin Adenocarcinoma (Cell Line: DLD1) [5]
Doxorubicin + Lapatinib DC5D8I4 Doxorubicin Amelanotic melanoma (Cell Line: A2058) [5]
Doxorubicin + Lapatinib DCS9VHE Doxorubicin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Doxorubicin + Lapatinib DCJK3HJ Doxorubicin Malignant melanoma (Cell Line: HT144) [5]
Doxorubicin + Lapatinib DCBAT0R Doxorubicin Malignant melanoma (Cell Line: RPMI7951) [5]
Doxorubicin + Lapatinib DC9NE70 Doxorubicin Malignant melanoma (Cell Line: UACC62) [5]
Doxorubicin + Lapatinib DC1YZXS Doxorubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Doxorubicin + Lapatinib DCK9UCK Doxorubicin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Doxorubicin + Lapatinib DC6ALBR Doxorubicin Breast carcinoma (Cell Line: OCUBM) [3]
Doxorubicin + Lapatinib DCEL7MG Doxorubicin Colon adenocarcinoma (Cell Line: LOVO) [3]
Doxorubicin + Lapatinib DCXAKAZ Doxorubicin Colon carcinoma (Cell Line: RKO) [3]
Doxorubicin + Lapatinib DC3YOS8 Doxorubicin Invasive ductal carcinoma (Cell Line: T-47D) [3]
Doxorubicin + Lapatinib DCKPCU6 Doxorubicin Rectal adenocarcinoma (Cell Line: SW837) [3]
Epirubicin + Lapatinib DC3SSV2 Epirubicin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Epirubicin + Lapatinib DCDF8EJ Epirubicin Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Epirubicin + Lapatinib DCOR3HF Epirubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Epirubicin + Lapatinib DCN2TNA Epirubicin Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Epirubicin + Lapatinib DCQ8QQ0 Epirubicin Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Epirubicin + Lapatinib DCGX5L0 Epirubicin Renal cell carcinoma (Cell Line: SN12C) [5]
Epirubicin + Lapatinib DC32774 Epirubicin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Lapatinib DCU1YK4 Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Lapatinib DC0X8CP Epirubicin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Lapatinib DC88SAQ Epirubicin Adenocarcinoma (Cell Line: HCT116) [4]
Epirubicin + Lapatinib DCXI5IP Epirubicin Adenocarcinoma (Cell Line: HT29) [4]
Epirubicin + Lapatinib DCEOB69 Epirubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Lapatinib DCP1M5U Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Lapatinib DC6A6EP Epirubicin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Epirubicin + Lapatinib DCHED89 Epirubicin Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + Lapatinib DC46TBK Epirubicin Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Lapatinib DCYD3FY Epirubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Lapatinib DC097BP Epirubicin Prostate carcinoma (Cell Line: PC-3) [4]
Estramustine + Lapatinib DC5LW4X Estramustine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Estramustine + Lapatinib DCS78EW Estramustine Astrocytoma (Cell Line: SNB-19) [5]
Estramustine + Lapatinib DCNYSFQ Estramustine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Estramustine + Lapatinib DCCHZAZ Estramustine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Estramustine + Lapatinib DC53W8K Estramustine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Estramustine + Lapatinib DCSKY5K Estramustine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Estramustine + Lapatinib DC6X31P Estramustine Breast carcinoma (Cell Line: OCUBM) [3]
Estramustine + Lapatinib DCPCMFB Estramustine Colon adenocarcinoma (Cell Line: LOVO) [3]
Estramustine + Lapatinib DCVT40H Estramustine Adenocarcinoma (Cell Line: A427) [4]
Estramustine + Lapatinib DCDKD5R Estramustine Adenocarcinoma (Cell Line: NCIH23) [4]
Estramustine + Lapatinib DCWN5Z7 Estramustine Adenocarcinoma (Cell Line: COLO320DM) [4]
Estramustine + Lapatinib DCPR9UN Estramustine Amelanotic melanoma (Cell Line: A2058) [4]
Estramustine + Lapatinib DCF3OJV Estramustine Malignant melanoma (Cell Line: A375) [4]
Estramustine + Lapatinib DCNX1PB Estramustine Malignant melanoma (Cell Line: RPMI7951) [4]
Estramustine + Lapatinib DC38H8P Estramustine Malignant melanoma (Cell Line: UACC62) [4]
Estramustine + Lapatinib DCZSLMU Estramustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Estramustine + Lapatinib DCO6WCA Estramustine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Etoposide + Lapatinib DCJKUYN Etoposide Adenocarcinoma (Cell Line: CAOV3) [5]
Etoposide + Lapatinib DC93UNY Etoposide Adenocarcinoma (Cell Line: A427) [5]
Etoposide + Lapatinib DC51YQZ Etoposide Adenocarcinoma (Cell Line: NCIH1650) [5]
Etoposide + Lapatinib DCJ2IA8 Etoposide Adenocarcinoma (Cell Line: NCIH2122) [5]
Etoposide + Lapatinib DC34QBY Etoposide Adenocarcinoma (Cell Line: NCIH520) [5]
Etoposide + Lapatinib DCNDOQJ Etoposide Adenocarcinoma (Cell Line: COLO320DM) [5]
Etoposide + Lapatinib DCM03AU Etoposide Adenocarcinoma (Cell Line: DLD1) [5]
Etoposide + Lapatinib DCJMOCK Etoposide Adenocarcinoma (Cell Line: HCT116) [5]
Etoposide + Lapatinib DCOR98A Etoposide Adenocarcinoma (Cell Line: HT29) [5]
Etoposide + Lapatinib DC7015V Etoposide Amelanotic melanoma (Cell Line: A2058) [5]
Etoposide + Lapatinib DCREIRF Etoposide Malignant melanoma (Cell Line: HT144) [5]
Etoposide + Lapatinib DCRV7CW Etoposide Malignant melanoma (Cell Line: RPMI7951) [5]
Etoposide + Lapatinib DCWOZPY Etoposide Malignant melanoma (Cell Line: SKMEL30) [5]
Etoposide + Lapatinib DCX5LG3 Etoposide Malignant melanoma (Cell Line: UACC62) [5]
Etoposide + Lapatinib DCIOBEW Etoposide Mesothelioma (Cell Line: MSTO) [5]
Etoposide + Lapatinib DCI7RNJ Etoposide Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Etoposide + Lapatinib DCXGS8O Etoposide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Etoposide + Lapatinib DCE4HR5 Etoposide Prostate carcinoma (Cell Line: LNCAP) [5]
Etoposide + Lapatinib DCH65TQ Etoposide Prostate carcinoma (Cell Line: VCAP) [5]
Etoposide + Lapatinib DCJUJ4V Etoposide Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Etoposide + Lapatinib DCWLF6D Etoposide Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Etoposide + Lapatinib DCNL6VW Etoposide Breast carcinoma (Cell Line: ZR751) [3]
Etoposide + Lapatinib DC2JMJ4 Etoposide Breast carcinoma (Cell Line: OCUBM) [3]
Etoposide + Lapatinib DCHC1VS Etoposide Carcinoma (Cell Line: MDAMB436) [3]
Etoposide + Lapatinib DCCXPRB Etoposide Colon adenocarcinoma (Cell Line: LOVO) [3]
Etoposide + Lapatinib DCSKTVU Etoposide Rectal adenocarcinoma (Cell Line: SW837) [3]
Fludarabine + Lapatinib DC5RZNI Fludarabine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Fludarabine + Lapatinib DC44OE7 Fludarabine Adenocarcinoma (Cell Line: HCT-15) [4]
Fluorouracil + Lapatinib DC042HW Fluorouracil Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Fluorouracil + Lapatinib DC6MMP7 Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Fluorouracil + Lapatinib DCN25FH Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Fluorouracil + Lapatinib DCDPWLJ Fluorouracil Breast carcinoma (Cell Line: KPL1) [3]
Fluorouracil + Lapatinib DCYNRI3 Fluorouracil Breast carcinoma (Cell Line: OCUBM) [3]
Fluorouracil + Lapatinib DCEPSYD Fluorouracil Carcinoma (Cell Line: OV90) [3]
Fluorouracil + Lapatinib DC3FD7A Fluorouracil Carcinoma (Cell Line: MDAMB436) [3]
Fluorouracil + Lapatinib DCQHOGW Fluorouracil Colon adenocarcinoma (Cell Line: LOVO) [3]
Fluorouracil + Lapatinib DCQYT8T Fluorouracil Colon carcinoma (Cell Line: RKO) [3]
Fluorouracil + Lapatinib DC5P376 Fluorouracil Invasive ductal carcinoma (Cell Line: T-47D) [3]
Fluorouracil + Lapatinib DCODSY6 Fluorouracil Rectal adenocarcinoma (Cell Line: SW837) [3]
Fluorouracil + Lapatinib DCE0NWM Fluorouracil Adenocarcinoma (Cell Line: CAOV3) [4]
Fluorouracil + Lapatinib DCPM3UR Fluorouracil Adenocarcinoma (Cell Line: OVCAR3) [4]
Fluorouracil + Lapatinib DC344QR Fluorouracil Adenocarcinoma (Cell Line: A427) [4]
Fluorouracil + Lapatinib DC8IL4R Fluorouracil Adenocarcinoma (Cell Line: NCIH1650) [4]
Fluorouracil + Lapatinib DCLOTM5 Fluorouracil Adenocarcinoma (Cell Line: NCIH2122) [4]
Fluorouracil + Lapatinib DCY3QKH Fluorouracil Adenocarcinoma (Cell Line: NCIH23) [4]
Fluorouracil + Lapatinib DCDZIFI Fluorouracil Adenocarcinoma (Cell Line: NCIH520) [4]
Fluorouracil + Lapatinib DCGF9B9 Fluorouracil Adenocarcinoma (Cell Line: COLO320DM) [4]
Fluorouracil + Lapatinib DCYXUSM Fluorouracil Adenocarcinoma (Cell Line: DLD1) [4]
Fluorouracil + Lapatinib DCV5BD5 Fluorouracil Adenocarcinoma (Cell Line: HCT116) [4]
Fluorouracil + Lapatinib DCDCQ05 Fluorouracil Adenocarcinoma (Cell Line: HT29) [4]
Fluorouracil + Lapatinib DCIP280 Fluorouracil Adenocarcinoma (Cell Line: SW-620) [4]
Fluorouracil + Lapatinib DCBOX6B Fluorouracil Amelanotic melanoma (Cell Line: A2058) [4]
Fluorouracil + Lapatinib DC2IGMG Fluorouracil Germ cell tumour (Cell Line: PA1) [4]
Fluorouracil + Lapatinib DCKVIMN Fluorouracil Malignant melanoma (Cell Line: A375) [4]
Fluorouracil + Lapatinib DCNRCUM Fluorouracil Malignant melanoma (Cell Line: HT144) [4]
Fluorouracil + Lapatinib DCJG998 Fluorouracil Malignant melanoma (Cell Line: RPMI7951) [4]
Fluorouracil + Lapatinib DCAC28O Fluorouracil Malignant melanoma (Cell Line: SKMEL30) [4]
Fluorouracil + Lapatinib DC1YNWU Fluorouracil Malignant melanoma (Cell Line: UACC62) [4]
Fluorouracil + Lapatinib DCLEWTG Fluorouracil Mesothelioma (Cell Line: MSTO) [4]
Fluorouracil + Lapatinib DCO7O18 Fluorouracil Non small cell carcinoma (Cell Line: SKMES1) [4]
Fluorouracil + Lapatinib DC3HPXN Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Fluorouracil + Lapatinib DC9CG9Q Fluorouracil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Fluorouracil + Lapatinib DCCVRAG Fluorouracil Prostate carcinoma (Cell Line: VCAP) [4]
Gefitinib + Lapatinib DC5AWO7 Gefitinib Adenocarcinoma (Cell Line: SW-620) [5]
Gefitinib + Lapatinib DCBVIMM Gefitinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Gefitinib + Lapatinib DCJ2DIY Gefitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Gefitinib + Lapatinib DCL2U68 Gefitinib Amelanotic melanoma (Cell Line: M14) [5]
Gefitinib + Lapatinib DCLCMX6 Gefitinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Gefitinib + Lapatinib DC0UEVY Gefitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Gefitinib + Lapatinib DCPAMBN Gefitinib Melanoma (Cell Line: UACC-257) [5]
Gefitinib + Lapatinib DCNR29C Gefitinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Gefitinib + Lapatinib DCQKB14 Gefitinib Colon adenocarcinoma (Cell Line: COLO 205) [3]
Gemcitabine + Lapatinib DCU3BNY Gemcitabine Adenocarcinoma (Cell Line: A427) [5]
Gemcitabine + Lapatinib DC2AP8F Gemcitabine Adenocarcinoma (Cell Line: NCIH2122) [5]
Gemcitabine + Lapatinib DCOWZBF Gemcitabine Adenocarcinoma (Cell Line: COLO320DM) [5]
Gemcitabine + Lapatinib DC91KLD Gemcitabine Adenocarcinoma (Cell Line: HT29) [5]
Gemcitabine + Lapatinib DC8FD8N Gemcitabine Amelanotic melanoma (Cell Line: A2058) [5]
Gemcitabine + Lapatinib DCX9C06 Gemcitabine Breast carcinoma (Cell Line: ZR751) [3]
Gemcitabine + Lapatinib DCLSOJT Gemcitabine Breast carcinoma (Cell Line: OCUBM) [3]
Idarubicin + Lapatinib DCKWOYB Idarubicin Glioma (Cell Line: SF-268) [5]
Idarubicin + Lapatinib DCX5ELE Idarubicin Carcinoma (Cell Line: MDAMB436) [3]
Idarubicin + Lapatinib DCRP3PA Idarubicin Adenocarcinoma (Cell Line: NCIH2122) [4]
Idarubicin + Lapatinib DCD1SOT Idarubicin Adenocarcinoma (Cell Line: NCIH23) [4]
Idarubicin + Lapatinib DCDNQBV Idarubicin Adenocarcinoma (Cell Line: HCT116) [4]
Idarubicin + Lapatinib DC00HWL Idarubicin Adenocarcinoma (Cell Line: SW-620) [4]
Idarubicin + Lapatinib DCC4E8I Idarubicin Amelanotic melanoma (Cell Line: A2058) [4]
Idarubicin + Lapatinib DCLFQLH Idarubicin Germ cell tumour (Cell Line: PA1) [4]
Idarubicin + Lapatinib DCFXD31 Idarubicin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Idarubicin + Lapatinib DC9A9VD Idarubicin Malignant melanoma (Cell Line: A375) [4]
Idarubicin + Lapatinib DCG9MF0 Idarubicin Malignant melanoma (Cell Line: RPMI7951) [4]
Idarubicin + Lapatinib DCKYM3W Idarubicin Malignant melanoma (Cell Line: UACC62) [4]
Idarubicin + Lapatinib DCDFID5 Idarubicin Mesothelioma (Cell Line: MSTO) [4]
Idarubicin + Lapatinib DCZZXSM Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Imatinib + Lapatinib DC5WBUY Imatinib Anaplastic large cell lymphoma (Cell Line: SR) [5]
Indazole derivative 5 + Lapatinib DCTO5KJ Indazole derivative 5 Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Indazole derivative 5 + Lapatinib DCB7C2C Indazole derivative 5 Invasive ductal carcinoma (Cell Line: BT-549) [3]
Indazole derivative 5 + Lapatinib DC8XI4I Indazole derivative 5 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Indazole derivative 5 + Lapatinib DCWAL30 Indazole derivative 5 Lung adenocarcinoma (Cell Line: HOP-62) [4]
JNK-IN-8 + Lapatinib DCIW3X1 JNK-IN-8 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Lapatinib + Fulvestrant DCEXSG5 Fulvestrant Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Lapatinib + PD-0325901 DCN0E7E PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Lapatinib + PD-0325901 DCL98IZ PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + PD-0325901 DCZY7TD PD-0325901 Breast carcinoma (Cell Line: ZR751) [3]
Lapatinib + PD-0325901 DC909I2 PD-0325901 Breast carcinoma (Cell Line: KPL1) [3]
Lapatinib + PD-0325901 DCBGYAK PD-0325901 Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + PD-0325901 DCGP215 PD-0325901 Carcinoma (Cell Line: OV90) [3]
Lapatinib + PD-0325901 DCK8EQV PD-0325901 Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + PD-0325901 DCMEXFB PD-0325901 Carcinoma (Cell Line: MDAMB436) [3]
Lapatinib + PD-0325901 DCJSORG PD-0325901 Colon adenocarcinoma (Cell Line: LOVO) [3]
Lapatinib + PD-0325901 DCJ5A6D PD-0325901 Colon carcinoma (Cell Line: RKO) [3]
Lapatinib + PD-0325901 DCJ3U73 PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [3]
Lapatinib + PD-0325901 DCUCGP5 PD-0325901 Rectal adenocarcinoma (Cell Line: SW837) [3]
Lapatinib + MK-1775 DC1B2O2 MK-1775 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + MK-1775 DCG942Q MK-1775 Breast carcinoma (Cell Line: KPL1) [3]
Lapatinib + MK-1775 DCBE7MQ MK-1775 Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + MK-1775 DCV0LXB MK-1775 Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + MK-1775 DCWF90P MK-1775 Carcinoma (Cell Line: MDAMB436) [3]
Lapatinib + MK-1775 DCXJ4B4 MK-1775 Colon adenocarcinoma (Cell Line: LOVO) [3]
Lapatinib + MK-1775 DCDQG8R MK-1775 Colon carcinoma (Cell Line: RKO) [3]
Lapatinib + MK-1775 DCVG4BJ MK-1775 Rectal adenocarcinoma (Cell Line: SW837) [3]
Lapatinib + Isoniazid DCZWKXC Isoniazid Carcinoma (Cell Line: RXF 393) [3]
Lapatinib + RTB101 DCEO6IL RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Lapatinib + RTB101 DCTPC9J RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + RTB101 DCARH2D RTB101 Breast carcinoma (Cell Line: ZR751) [3]
Lapatinib + RTB101 DCE9R98 RTB101 Breast carcinoma (Cell Line: KPL1) [3]
Lapatinib + RTB101 DC8PAWZ RTB101 Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + RTB101 DCUHRPH RTB101 Carcinoma (Cell Line: OV90) [3]
Lapatinib + RTB101 DCJUEHG RTB101 Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + RTB101 DCK428S RTB101 Carcinoma (Cell Line: MDAMB436) [3]
Lapatinib + RTB101 DCXZFWY RTB101 Colon adenocarcinoma (Cell Line: LOVO) [3]
Lapatinib + RTB101 DC9JWMG RTB101 Colon carcinoma (Cell Line: RKO) [3]
Lapatinib + RTB101 DCOR7OW RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [3]
Lapatinib + RTB101 DC0A69K RTB101 Rectal adenocarcinoma (Cell Line: SW837) [3]
Lapatinib + SCH-900776 DCCLPD0 SCH-900776 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + SCH-900776 DCCZ72M SCH-900776 Breast carcinoma (Cell Line: KPL1) [3]
Lapatinib + SCH-900776 DC3V4IY SCH-900776 Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + SCH-900776 DCVPY1B SCH-900776 Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + SCH-900776 DCXKUTJ SCH-900776 Carcinoma (Cell Line: MDAMB436) [3]
Lapatinib + SCH-900776 DCJ6ADC SCH-900776 Colon adenocarcinoma (Cell Line: LOVO) [3]
Lapatinib + SCH-900776 DCYN8E6 SCH-900776 Colon carcinoma (Cell Line: RKO) [3]
Lapatinib + SCH-900776 DCVQ0S3 SCH-900776 Rectal adenocarcinoma (Cell Line: SW837) [3]
Lapatinib + Plicamycin DCXWDHL Plicamycin Carcinoma (Cell Line: MCF7) [3]
Lapatinib + Triapine DCXXWIK Triapine Carcinoma (Cell Line: RXF 393) [3]
Lapatinib + 10-hydroxycamptothecin DCMK5L0 10-hydroxycamptothecin Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Lapatinib + 10-hydroxycamptothecin DCMVN2J 10-hydroxycamptothecin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + 10-hydroxycamptothecin DCYY5QV 10-hydroxycamptothecin Breast carcinoma (Cell Line: KPL1) [3]
Lapatinib + 10-hydroxycamptothecin DCABNXY 10-hydroxycamptothecin Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + 10-hydroxycamptothecin DCMB29X 10-hydroxycamptothecin Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + 10-hydroxycamptothecin DCVV5JB 10-hydroxycamptothecin Carcinoma (Cell Line: MDAMB436) [3]
Lapatinib + 10-hydroxycamptothecin DC8PSQC 10-hydroxycamptothecin Colon adenocarcinoma (Cell Line: LOVO) [3]
Lapatinib + 10-hydroxycamptothecin DC3G8OR 10-hydroxycamptothecin Colon carcinoma (Cell Line: RKO) [3]
Lapatinib + 10-hydroxycamptothecin DCWB95I 10-hydroxycamptothecin Rectal adenocarcinoma (Cell Line: SW837) [3]
Lapatinib + Pralatrexate DC5EUV5 Pralatrexate Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Lapatinib + SNX-2112 DCNAMUN SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Lapatinib + SNX-2112 DCZM7L6 SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + SNX-2112 DC6WQ5P SNX-2112 Breast carcinoma (Cell Line: KPL1) [3]
Lapatinib + SNX-2112 DCHQLIL SNX-2112 Carcinoma (Cell Line: MDAMB436) [3]
Lapatinib + SNX-2112 DC3BAJ6 SNX-2112 Colon adenocarcinoma (Cell Line: LOVO) [3]
Lapatinib + SNX-2112 DCG8MNS SNX-2112 Colon carcinoma (Cell Line: RKO) [3]
Lapatinib + SNX-2112 DC6V0RQ SNX-2112 Invasive ductal carcinoma (Cell Line: T-47D) [3]
Lapatinib + SNX-2112 DCIHF76 SNX-2112 Rectal adenocarcinoma (Cell Line: SW837) [3]
Lapatinib + Erlotinib DCD6B4L Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Lapatinib + Erlotinib DCE34OB Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + Erlotinib DCRZWQR Erlotinib Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + Erlotinib DCKG5NK Erlotinib Carcinoma (Cell Line: OV90) [3]
Lapatinib + Erlotinib DCMC89G Erlotinib Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + Ifosfamide DCZ60GD Ifosfamide Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Lapatinib + MK-5108 DCWIP4F MK-5108 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Lapatinib + MK-5108 DC857MR MK-5108 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + MK-5108 DCJ3GIX MK-5108 Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + MK-5108 DCDUNLJ MK-5108 Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + MK-5108 DCM8K8T MK-5108 Colon adenocarcinoma (Cell Line: LOVO) [3]
Lapatinib + MK-5108 DCVCROF MK-5108 Colon carcinoma (Cell Line: RKO) [3]
Lapatinib + Bendamustine hydrochloride DCQUVH4 Bendamustine hydrochloride Colon carcinoma (Cell Line: KM12) [3]
Lapatinib + Altretamine DCW1S71 Altretamine Carcinoma (Cell Line: RXF 393) [3]
Lapatinib + Ridaforolimus DCWAAUK Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Lapatinib + Ridaforolimus DC8HVA8 Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + Ridaforolimus DCY0OS1 Ridaforolimus Breast carcinoma (Cell Line: KPL1) [3]
Lapatinib + Ridaforolimus DCMP7O2 Ridaforolimus Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + Ridaforolimus DCNGB7O Ridaforolimus Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + Ridaforolimus DCNJLIT Ridaforolimus Carcinoma (Cell Line: MDAMB436) [3]
Lapatinib + Ridaforolimus DCSFJHE Ridaforolimus Colon carcinoma (Cell Line: RKO) [3]
Lapatinib + Ridaforolimus DC67AO2 Ridaforolimus Invasive ductal carcinoma (Cell Line: T-47D) [3]
Lapatinib + Ridaforolimus DCVLOIM Ridaforolimus Rectal adenocarcinoma (Cell Line: SW837) [3]
Lapatinib + MK-4827 DCG9MUY MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Lapatinib + MK-4827 DCROE3V MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + MK-4827 DCS3PIE MK-4827 Breast carcinoma (Cell Line: KPL1) [3]
Lapatinib + MK-4827 DCMC3RW MK-4827 Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + MK-4827 DCC07FH MK-4827 Carcinoma (Cell Line: OV90) [3]
Lapatinib + MK-4827 DCSS3E4 MK-4827 Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + MK-4827 DCZWCW6 MK-4827 Colon adenocarcinoma (Cell Line: LOVO) [3]
Lapatinib + MK-4827 DCQNGK7 MK-4827 Colon carcinoma (Cell Line: RKO) [3]
Lapatinib + MK-4827 DCBFK0L MK-4827 Invasive ductal carcinoma (Cell Line: T-47D) [3]
Lapatinib + MK-4827 DCNZHJ5 MK-4827 Rectal adenocarcinoma (Cell Line: SW837) [3]
Lapatinib + Lomustine DCXQM7K Lomustine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Lapatinib + Lomustine DCYLA46 Lomustine Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + Lomustine DC656PZ Lomustine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Lapatinib + Bortezomib DCEKXFJ Bortezomib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + Bortezomib DC5BCWW Bortezomib Breast carcinoma (Cell Line: KPL1) [3]
Lapatinib + Bortezomib DCCBYRL Bortezomib Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + Bortezomib DCPQ4WH Bortezomib Colon adenocarcinoma (Cell Line: LOVO) [3]
Lapatinib + Bortezomib DC868SC Bortezomib Rectal adenocarcinoma (Cell Line: SW837) [3]
Lapatinib + GSK525762 DCZYH53 GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Lapatinib + GSK525762 DC711JG GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + GSK525762 DCLK50I GSK525762 Breast carcinoma (Cell Line: KPL1) [3]
Lapatinib + Sorafenib DC7ALR8 Sorafenib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Lapatinib + Sorafenib DCR4SGU Sorafenib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + Sorafenib DC9KZXQ Sorafenib Breast carcinoma (Cell Line: ZR751) [3]
Lapatinib + Sorafenib DCA2IP7 Sorafenib Breast carcinoma (Cell Line: KPL1) [3]
Lapatinib + Sorafenib DCUW80A Sorafenib Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + Sorafenib DCXPOE3 Sorafenib Carcinoma (Cell Line: OV90) [3]
Lapatinib + Sorafenib DCTI7OA Sorafenib Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + Sorafenib DC22NZD Sorafenib Colon carcinoma (Cell Line: RKO) [3]
Lapatinib + Sorafenib DC4S4KY Sorafenib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Lapatinib + Sorafenib DCG8IDD Sorafenib Rectal adenocarcinoma (Cell Line: SW837) [3]
Lapatinib + MK-2206 DC3R796 MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Lapatinib + MK-2206 DCT0I92 MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + MK-2206 DCAYZK0 MK-2206 Breast carcinoma (Cell Line: ZR751) [3]
Lapatinib + MK-2206 DC7IBU4 MK-2206 Breast carcinoma (Cell Line: KPL1) [3]
Lapatinib + MK-2206 DCSKIAU MK-2206 Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + MK-2206 DCP0JBD MK-2206 Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + MK-2206 DCG52ZA MK-2206 Colon carcinoma (Cell Line: RKO) [3]
Lapatinib + MK-2206 DCRMVVH MK-2206 Rectal adenocarcinoma (Cell Line: SW837) [3]
Lapatinib + Pomalidomide DCKY3A1 Pomalidomide Carcinoma (Cell Line: RXF 393) [3]
Lapatinib + Pomalidomide DCVOF1G Pomalidomide Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Lapatinib + Vinflunine DCA5V4P Vinflunine Carcinoma (Cell Line: MCF7) [3]
Lapatinib + Vinflunine DCYP1TC Vinflunine Colon carcinoma (Cell Line: KM12) [3]
Lapatinib + Vinflunine DCZXFTC Vinflunine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Lapatinib + Vinflunine DC4NCSD Vinflunine Invasive ductal carcinoma (Cell Line: BT-549) [3]
Lapatinib + PMID28870136-Compound-43 DCXBA8O PMID28870136-Compound-43 Colon carcinoma (Cell Line: KM12) [3]
Lapatinib + Vorinostat DC1AOH0 Vorinostat Breast carcinoma (Cell Line: ZR751) [3]
Lapatinib + Vorinostat DCOGIEF Vorinostat Breast carcinoma (Cell Line: KPL1) [3]
Lapatinib + Vorinostat DC7YAUN Vorinostat Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + Vorinostat DCN0EME Vorinostat Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + Vorinostat DC256VK Vorinostat Colon carcinoma (Cell Line: RKO) [3]
Lapatinib + Dasatinib DCRL7YN Dasatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Lapatinib + Dasatinib DCZE45W Dasatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Lapatinib + Dasatinib DCDBPDI Dasatinib Breast carcinoma (Cell Line: KPL1) [3]
Lapatinib + Dasatinib DC20MCK Dasatinib Breast carcinoma (Cell Line: OCUBM) [3]
Lapatinib + Dasatinib DC5ZUNQ Dasatinib Carcinoma (Cell Line: OV90) [3]
Lapatinib + Dasatinib DC3HX6E Dasatinib Carcinoma (Cell Line: EFM192B) [3]
Lapatinib + Dasatinib DCQW0V2 Dasatinib Colon carcinoma (Cell Line: RKO) [3]
Lapatinib + Dasatinib DCIXM1A Dasatinib Rectal adenocarcinoma (Cell Line: SW837) [3]
Lapatinib + Pentostatin DCVW9P5 Pentostatin Adenocarcinoma (Cell Line: HCT-15) [4]
Lapatinib + Pentostatin DCL074P Pentostatin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Lapatinib + Pentostatin DC9CQAW Pentostatin Glioma (Cell Line: SF-539) [4]
Lapatinib + Fulvestrant DC7YNQ6 Fulvestrant Adenocarcinoma (Cell Line: SW-620) [4]
Lapatinib + PD-0325901 DCJLIXT PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + PD-0325901 DCQDUXE PD-0325901 Adenocarcinoma (Cell Line: OVCAR3) [4]
Lapatinib + PD-0325901 DCI4N4J PD-0325901 Adenocarcinoma (Cell Line: A427) [4]
Lapatinib + PD-0325901 DCN9156 PD-0325901 Adenocarcinoma (Cell Line: NCIH1650) [4]
Lapatinib + PD-0325901 DC7Q9B6 PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [4]
Lapatinib + PD-0325901 DCWPX30 PD-0325901 Adenocarcinoma (Cell Line: NCIH23) [4]
Lapatinib + PD-0325901 DC078BX PD-0325901 Adenocarcinoma (Cell Line: NCIH520) [4]
Lapatinib + PD-0325901 DCQMU7N PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + PD-0325901 DCWGBCD PD-0325901 Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + PD-0325901 DCHBSZJ PD-0325901 Adenocarcinoma (Cell Line: HT29) [4]
Lapatinib + PD-0325901 DC5OTT4 PD-0325901 Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + PD-0325901 DCO4MNH PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + PD-0325901 DCZ9V28 PD-0325901 Germ cell tumour (Cell Line: PA1) [4]
Lapatinib + PD-0325901 DCGNIMN PD-0325901 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Lapatinib + PD-0325901 DCGTD23 PD-0325901 Malignant melanoma (Cell Line: HT144) [4]
Lapatinib + PD-0325901 DCS4RNP PD-0325901 Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + PD-0325901 DCFVMNF PD-0325901 Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + PD-0325901 DCSAETK PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + PD-0325901 DC0YFC7 PD-0325901 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Lapatinib + PD-0325901 DCAII4H PD-0325901 Prostate carcinoma (Cell Line: LNCAP) [4]
Lapatinib + PD-0325901 DCMOFZ7 PD-0325901 Prostate carcinoma (Cell Line: VCAP) [4]
Lapatinib + Ixabepilone DCQAZJN Ixabepilone Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Lapatinib + Ixabepilone DCXH0P2 Ixabepilone Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Lapatinib + Ixabepilone DCGWFE4 Ixabepilone Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Lapatinib + Dactinomycin DCSXWTY Dactinomycin Adenocarcinoma (Cell Line: OVCAR3) [4]
Lapatinib + MK-1775 DCWQWWZ MK-1775 Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + MK-1775 DCHK8J8 MK-1775 Adenocarcinoma (Cell Line: A427) [4]
Lapatinib + MK-1775 DC1ZD85 MK-1775 Adenocarcinoma (Cell Line: NCIH2122) [4]
Lapatinib + MK-1775 DCEILRL MK-1775 Adenocarcinoma (Cell Line: NCIH520) [4]
Lapatinib + MK-1775 DC2QLEZ MK-1775 Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + MK-1775 DCY0VCX MK-1775 Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + MK-1775 DCHSU4T MK-1775 Adenocarcinoma (Cell Line: HCT116) [4]
Lapatinib + MK-1775 DCTBR5P MK-1775 Adenocarcinoma (Cell Line: HT29) [4]
Lapatinib + MK-1775 DC21Q7Q MK-1775 Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + MK-1775 DCRLKOF MK-1775 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + MK-1775 DCQ06O0 MK-1775 Germ cell tumour (Cell Line: PA1) [4]
Lapatinib + MK-1775 DCDY7WK MK-1775 Malignant melanoma (Cell Line: A375) [4]
Lapatinib + MK-1775 DCGE571 MK-1775 Malignant melanoma (Cell Line: HT144) [4]
Lapatinib + MK-1775 DCQJQ3Q MK-1775 Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + MK-1775 DCUDG1U MK-1775 Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + MK-1775 DC79KEQ MK-1775 Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + MK-1775 DCYTAS1 MK-1775 Mesothelioma (Cell Line: MSTO) [4]
Lapatinib + MK-1775 DCFHHSE MK-1775 Non small cell carcinoma (Cell Line: SKMES1) [4]
Lapatinib + MK-1775 DCQ4R64 MK-1775 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + MK-1775 DCDIBWQ MK-1775 Prostate carcinoma (Cell Line: VCAP) [4]
Lapatinib + Cyclophosphamide DCF25SR Cyclophosphamide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Lapatinib + Cyclophosphamide DCPQE5Y Cyclophosphamide Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Lapatinib + Cyclophosphamide DCC2WFR Cyclophosphamide Astrocytoma (Cell Line: SNB-19) [4]
Lapatinib + Cyclophosphamide DCNLHG6 Cyclophosphamide Glioma (Cell Line: SF-539) [4]
Lapatinib + Cyclophosphamide DCXV3R2 Cyclophosphamide Lung adenocarcinoma (Cell Line: HOP-62) [4]
Lapatinib + Cyclophosphamide DCWDMNV Cyclophosphamide Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + Cyclophosphamide DCNKUFW Cyclophosphamide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Lapatinib + Methotrexate DCYK6YC Methotrexate Anaplastic large cell lymphoma (Cell Line: SR) [4]
Lapatinib + Isoniazid DCVW745 Isoniazid Astrocytoma (Cell Line: SNB-19) [4]
Lapatinib + Isoniazid DC97C8S Isoniazid Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Lapatinib + Isoniazid DCPODS1 Isoniazid Glioma (Cell Line: SF-295) [4]
Lapatinib + Isoniazid DCJA0GA Isoniazid Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + Arsenic trioxide DC6DUR0 Arsenic trioxide Adenocarcinoma (Cell Line: A549) [4]
Lapatinib + Arsenic trioxide DCR8JFE Arsenic trioxide Melanoma (Cell Line: UACC-257) [4]
Lapatinib + RTB101 DC1QQY0 RTB101 Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + RTB101 DC8UFPF RTB101 Adenocarcinoma (Cell Line: A427) [4]
Lapatinib + RTB101 DCPPUAI RTB101 Adenocarcinoma (Cell Line: NCIH2122) [4]
Lapatinib + RTB101 DCQCC9K RTB101 Adenocarcinoma (Cell Line: NCIH23) [4]
Lapatinib + RTB101 DCLG5O1 RTB101 Adenocarcinoma (Cell Line: NCIH520) [4]
Lapatinib + RTB101 DCU28IT RTB101 Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + RTB101 DCMAOGS RTB101 Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + RTB101 DCJDKCX RTB101 Adenocarcinoma (Cell Line: HT29) [4]
Lapatinib + RTB101 DCYDYLZ RTB101 Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + RTB101 DCV9EV8 RTB101 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + RTB101 DC7LEZX RTB101 Malignant melanoma (Cell Line: HT144) [4]
Lapatinib + RTB101 DC53J8N RTB101 Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + RTB101 DCZUYOE RTB101 Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + RTB101 DCBRVXC RTB101 Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + RTB101 DC5LURT RTB101 Non small cell carcinoma (Cell Line: SKMES1) [4]
Lapatinib + RTB101 DCV4HEM RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + RTB101 DCEKO7A RTB101 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Lapatinib + RTB101 DCVV38E RTB101 Prostate carcinoma (Cell Line: VCAP) [4]
Lapatinib + SCH-900776 DCPRZL1 SCH-900776 Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + SCH-900776 DC4UVY1 SCH-900776 Adenocarcinoma (Cell Line: OVCAR3) [4]
Lapatinib + SCH-900776 DCIJHN8 SCH-900776 Adenocarcinoma (Cell Line: A427) [4]
Lapatinib + SCH-900776 DC7NQHO SCH-900776 Adenocarcinoma (Cell Line: NCIH2122) [4]
Lapatinib + SCH-900776 DC7KLHI SCH-900776 Adenocarcinoma (Cell Line: NCIH23) [4]
Lapatinib + SCH-900776 DCWTFQ8 SCH-900776 Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + SCH-900776 DCPHQOE SCH-900776 Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + SCH-900776 DC7UJ88 SCH-900776 Adenocarcinoma (Cell Line: HCT116) [4]
Lapatinib + SCH-900776 DCV8M0G SCH-900776 Adenocarcinoma (Cell Line: HT29) [4]
Lapatinib + SCH-900776 DCYVBUC SCH-900776 Adenocarcinoma (Cell Line: SW-620) [4]
Lapatinib + SCH-900776 DC34WMZ SCH-900776 Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + SCH-900776 DC67BV5 SCH-900776 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + SCH-900776 DCROA3T SCH-900776 Germ cell tumour (Cell Line: PA1) [4]
Lapatinib + SCH-900776 DCW9V02 SCH-900776 Malignant melanoma (Cell Line: A375) [4]
Lapatinib + SCH-900776 DCA7DTL SCH-900776 Malignant melanoma (Cell Line: HT144) [4]
Lapatinib + SCH-900776 DC90EQ2 SCH-900776 Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + SCH-900776 DC0J01A SCH-900776 Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + SCH-900776 DCU8MEA SCH-900776 Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + SCH-900776 DCASJ1H SCH-900776 Mesothelioma (Cell Line: MSTO) [4]
Lapatinib + SCH-900776 DCG2N6S SCH-900776 Non small cell carcinoma (Cell Line: SKMES1) [4]
Lapatinib + SCH-900776 DCNC1ZV SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + SCH-900776 DCOCDIM SCH-900776 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Lapatinib + SCH-900776 DCRWOTM SCH-900776 Prostate carcinoma (Cell Line: LNCAP) [4]
Lapatinib + SCH-900776 DCAQIEP SCH-900776 Prostate carcinoma (Cell Line: VCAP) [4]
Lapatinib + Plicamycin DCTMUHM Plicamycin Adenocarcinoma (Cell Line: NCIH23) [4]
Lapatinib + Plicamycin DC5U7BN Plicamycin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Lapatinib + Plicamycin DCUP5BW Plicamycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Lapatinib + Plicamycin DCT25PK Plicamycin Melanoma (Cell Line: MALME-3M) [4]
Lapatinib + Triapine DCBZ3OI Triapine Adenocarcinoma (Cell Line: DU-145) [4]
Lapatinib + Triapine DCWKW4S Triapine Adenocarcinoma (Cell Line: OVCAR3) [4]
Lapatinib + Triapine DCOFI5E Triapine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Lapatinib + Triapine DCHHBM1 Triapine Astrocytoma (Cell Line: U251) [4]
Lapatinib + Triapine DCBUDLX Triapine Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Lapatinib + Triapine DCUN5DA Triapine Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Lapatinib + Triapine DCFSL6P Triapine Glioma (Cell Line: SF-268) [4]
Lapatinib + Triapine DCYQ8UP Triapine Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + Triapine DCMSBHG Triapine Melanoma (Cell Line: UACC-257) [4]
Lapatinib + Triapine DCKIIYA Triapine Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Lapatinib + 10-hydroxycamptothecin DCEEF8Q 10-hydroxycamptothecin Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + 10-hydroxycamptothecin DCK2ECZ 10-hydroxycamptothecin Adenocarcinoma (Cell Line: OVCAR3) [4]
Lapatinib + 10-hydroxycamptothecin DCICV7F 10-hydroxycamptothecin Adenocarcinoma (Cell Line: A427) [4]
Lapatinib + 10-hydroxycamptothecin DCBPWTC 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH1650) [4]
Lapatinib + 10-hydroxycamptothecin DC8UDM5 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH2122) [4]
Lapatinib + 10-hydroxycamptothecin DCKUWWT 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH23) [4]
Lapatinib + 10-hydroxycamptothecin DCTXZ1H 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH520) [4]
Lapatinib + 10-hydroxycamptothecin DCMTCJY 10-hydroxycamptothecin Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + 10-hydroxycamptothecin DC5RSD2 10-hydroxycamptothecin Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + 10-hydroxycamptothecin DC0FXKV 10-hydroxycamptothecin Adenocarcinoma (Cell Line: HCT116) [4]
Lapatinib + 10-hydroxycamptothecin DC5OR6V 10-hydroxycamptothecin Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + 10-hydroxycamptothecin DCMYLNI 10-hydroxycamptothecin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + 10-hydroxycamptothecin DC58MBB 10-hydroxycamptothecin Germ cell tumour (Cell Line: PA1) [4]
Lapatinib + 10-hydroxycamptothecin DCPANJV 10-hydroxycamptothecin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Lapatinib + 10-hydroxycamptothecin DC9W1EE 10-hydroxycamptothecin Malignant melanoma (Cell Line: HT144) [4]
Lapatinib + 10-hydroxycamptothecin DC40JSC 10-hydroxycamptothecin Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + 10-hydroxycamptothecin DC2CGAW 10-hydroxycamptothecin Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + 10-hydroxycamptothecin DCL4VEE 10-hydroxycamptothecin Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + 10-hydroxycamptothecin DCJCCX4 10-hydroxycamptothecin Mesothelioma (Cell Line: MSTO) [4]
Lapatinib + 10-hydroxycamptothecin DC6LWIP 10-hydroxycamptothecin Non small cell carcinoma (Cell Line: SKMES1) [4]
Lapatinib + 10-hydroxycamptothecin DCICFPV 10-hydroxycamptothecin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + 10-hydroxycamptothecin DC78PYN 10-hydroxycamptothecin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Lapatinib + 10-hydroxycamptothecin DCSCOXK 10-hydroxycamptothecin Prostate carcinoma (Cell Line: VCAP) [4]
Lapatinib + Pralatrexate DCICA2U Pralatrexate Adenocarcinoma (Cell Line: HCT116) [4]
Lapatinib + Pralatrexate DCBA6TH Pralatrexate Glioma (Cell Line: SF-268) [4]
Lapatinib + Pralatrexate DCQROGI Pralatrexate Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Lapatinib + Pralatrexate DC5N8P0 Pralatrexate Prostate carcinoma (Cell Line: PC-3) [4]
Lapatinib + SNX-2112 DC3AC42 SNX-2112 Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + SNX-2112 DCUTWQC SNX-2112 Adenocarcinoma (Cell Line: OVCAR3) [4]
Lapatinib + SNX-2112 DC3J2XN SNX-2112 Adenocarcinoma (Cell Line: A427) [4]
Lapatinib + SNX-2112 DCR3I9B SNX-2112 Adenocarcinoma (Cell Line: NCIH1650) [4]
Lapatinib + SNX-2112 DC241AL SNX-2112 Adenocarcinoma (Cell Line: NCIH2122) [4]
Lapatinib + SNX-2112 DCD6UTH SNX-2112 Adenocarcinoma (Cell Line: NCIH23) [4]
Lapatinib + SNX-2112 DCQKABK SNX-2112 Adenocarcinoma (Cell Line: NCIH520) [4]
Lapatinib + SNX-2112 DC7U9YE SNX-2112 Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + SNX-2112 DC8XVLW SNX-2112 Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + SNX-2112 DCQ4HR0 SNX-2112 Adenocarcinoma (Cell Line: HCT116) [4]
Lapatinib + SNX-2112 DCF8Y6M SNX-2112 Adenocarcinoma (Cell Line: HT29) [4]
Lapatinib + SNX-2112 DCDSVWU SNX-2112 Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + SNX-2112 DCBCI1Q SNX-2112 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + SNX-2112 DCGKHYX SNX-2112 Germ cell tumour (Cell Line: PA1) [4]
Lapatinib + SNX-2112 DCKO0EK SNX-2112 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Lapatinib + SNX-2112 DCAJOI2 SNX-2112 Malignant melanoma (Cell Line: HT144) [4]
Lapatinib + SNX-2112 DCFDE92 SNX-2112 Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + SNX-2112 DCRYVPD SNX-2112 Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + SNX-2112 DCI8CQZ SNX-2112 Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + SNX-2112 DC36V6H SNX-2112 Non small cell carcinoma (Cell Line: SKMES1) [4]
Lapatinib + SNX-2112 DCH8QSO SNX-2112 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + SNX-2112 DCVD3V9 SNX-2112 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Lapatinib + SNX-2112 DC6OTA8 SNX-2112 Prostate carcinoma (Cell Line: LNCAP) [4]
Lapatinib + SNX-2112 DCGOS7K SNX-2112 Prostate carcinoma (Cell Line: VCAP) [4]
Lapatinib + Terameprocol DC6EI9S Terameprocol Adenocarcinoma (Cell Line: SW-620) [4]
Lapatinib + Terameprocol DC2QRLQ Terameprocol Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Lapatinib + Terameprocol DCM0HF2 Terameprocol Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + SCH 727965 DCN6P3D SCH 727965 Adenocarcinoma (Cell Line: HT29) [4]
Lapatinib + SCH 727965 DCQM0BR SCH 727965 Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Lapatinib + SCH 727965 DCXAHNE SCH 727965 Astrocytoma (Cell Line: U251) [4]
Lapatinib + Erlotinib DC8SBDV Erlotinib Adenocarcinoma (Cell Line: A427) [4]
Lapatinib + Erlotinib DCXXX1P Erlotinib Adenocarcinoma (Cell Line: NCIH2122) [4]
Lapatinib + Erlotinib DC81U1C Erlotinib Adenocarcinoma (Cell Line: NCIH520) [4]
Lapatinib + Erlotinib DCYBSA7 Erlotinib Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + Erlotinib DC1NGLF Erlotinib Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + Erlotinib DC8EGOU Erlotinib Adenocarcinoma (Cell Line: HT29) [4]
Lapatinib + Erlotinib DC6R27Z Erlotinib Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + Erlotinib DCHK3Q3 Erlotinib Germ cell tumour (Cell Line: PA1) [4]
Lapatinib + Erlotinib DC42OPM Erlotinib Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + Erlotinib DCC65MV Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + Erlotinib DCSDOD2 Erlotinib Prostate carcinoma (Cell Line: LNCAP) [4]
Lapatinib + Ifosfamide DCG8XU8 Ifosfamide Adenocarcinoma (Cell Line: HT29) [4]
Lapatinib + Ifosfamide DC22N8K Ifosfamide Amelanotic melanoma (Cell Line: M14) [4]
Lapatinib + Ifosfamide DC5JK9I Ifosfamide Glioma (Cell Line: SF-295) [4]
Lapatinib + Ifosfamide DC5NISX Ifosfamide Glioma (Cell Line: SF-539) [4]
Lapatinib + Ifosfamide DCX2GME Ifosfamide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Lapatinib + Ifosfamide DCTHPEN Ifosfamide Prostate carcinoma (Cell Line: PC-3) [4]
Lapatinib + MK-5108 DCGBWQ7 MK-5108 Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + MK-5108 DCBUJM5 MK-5108 Adenocarcinoma (Cell Line: OVCAR3) [4]
Lapatinib + MK-5108 DC5JDCW MK-5108 Adenocarcinoma (Cell Line: A427) [4]
Lapatinib + MK-5108 DC74E5U MK-5108 Adenocarcinoma (Cell Line: NCIH1650) [4]
Lapatinib + MK-5108 DCCA7UO MK-5108 Adenocarcinoma (Cell Line: NCIH23) [4]
Lapatinib + MK-5108 DC6IYBF MK-5108 Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + MK-5108 DC1YJUD MK-5108 Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + MK-5108 DCLZLZF MK-5108 Adenocarcinoma (Cell Line: HCT116) [4]
Lapatinib + MK-5108 DCD36I8 MK-5108 Adenocarcinoma (Cell Line: HT29) [4]
Lapatinib + MK-5108 DC3JF88 MK-5108 Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + MK-5108 DC346TM MK-5108 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + MK-5108 DC6HQTJ MK-5108 Malignant melanoma (Cell Line: A375) [4]
Lapatinib + MK-5108 DCXLBD2 MK-5108 Malignant melanoma (Cell Line: HT144) [4]
Lapatinib + MK-5108 DCIZ5SN MK-5108 Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + MK-5108 DC2LUNB MK-5108 Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + MK-5108 DCF8N2D MK-5108 Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + MK-5108 DC56TEL MK-5108 Mesothelioma (Cell Line: MSTO) [4]
Lapatinib + MK-5108 DCZ4ZT5 MK-5108 Non small cell carcinoma (Cell Line: SKMES1) [4]
Lapatinib + MK-5108 DCDIUAT MK-5108 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + MK-5108 DCYFM9K MK-5108 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Lapatinib + MK-5108 DCC9HJ7 MK-5108 Prostate carcinoma (Cell Line: VCAP) [4]
Lapatinib + Mitomycin DCZAGR9 Mitomycin Adenocarcinoma (Cell Line: DU-145) [4]
Lapatinib + Mitomycin DC4D3WM Mitomycin Adenocarcinoma (Cell Line: A549) [4]
Lapatinib + Mitomycin DCUYSK5 Mitomycin Adenocarcinoma (Cell Line: HCC-2998) [4]
Lapatinib + Mitomycin DC1MNCT Mitomycin Adenocarcinoma (Cell Line: HCT116) [4]
Lapatinib + Mitomycin DC66HYP Mitomycin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Lapatinib + Mitomycin DC3U84V Mitomycin Melanoma (Cell Line: MALME-3M) [4]
Lapatinib + Mitomycin DC50YMI Mitomycin Renal cell carcinoma (Cell Line: UO-31) [4]
Lapatinib + Altretamine DCYKWZG Altretamine Astrocytoma (Cell Line: SNB-19) [4]
Lapatinib + Altretamine DCPL6ER Altretamine Chronic myelogenous leukemia (Cell Line: K-562) [4]
Lapatinib + Altretamine DC6ZUSV Altretamine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Lapatinib + Altretamine DCSQFXI Altretamine Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + Ridaforolimus DCR7RQ8 Ridaforolimus Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + Ridaforolimus DCXVROI Ridaforolimus Adenocarcinoma (Cell Line: NCIH1650) [4]
Lapatinib + Ridaforolimus DC4XGCD Ridaforolimus Adenocarcinoma (Cell Line: NCIH2122) [4]
Lapatinib + Ridaforolimus DCP7287 Ridaforolimus Adenocarcinoma (Cell Line: NCIH23) [4]
Lapatinib + Ridaforolimus DC0CIAD Ridaforolimus Adenocarcinoma (Cell Line: NCIH520) [4]
Lapatinib + Ridaforolimus DCWC6LW Ridaforolimus Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + Ridaforolimus DC5O3XS Ridaforolimus Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + Ridaforolimus DC66JPI Ridaforolimus Adenocarcinoma (Cell Line: HCT116) [4]
Lapatinib + Ridaforolimus DCNWRA3 Ridaforolimus Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + Ridaforolimus DC8NE1P Ridaforolimus Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + Ridaforolimus DC60AWK Ridaforolimus Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + Ridaforolimus DCW8KCC Ridaforolimus Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + Ridaforolimus DCIO4YZ Ridaforolimus Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + Ridaforolimus DCBE837 Ridaforolimus Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + Ridaforolimus DCNQ2OQ Ridaforolimus Prostate carcinoma (Cell Line: LNCAP) [4]
Lapatinib + TEM DC8MRNT TEM Adenocarcinoma (Cell Line: HT29) [4]
Lapatinib + TEM DCQA4Z4 TEM Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Lapatinib + TEM DC17218 TEM Glioma (Cell Line: SF-295) [4]
Lapatinib + TEM DCMH100 TEM Lung adenocarcinoma (Cell Line: HOP-62) [4]
Lapatinib + TEM DC9AGA4 TEM Malignant melanoma (Cell Line: LOX IMVI) [4]
Lapatinib + MK-4827 DCNMQNC MK-4827 Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + MK-4827 DCAZA14 MK-4827 Adenocarcinoma (Cell Line: NCIH1650) [4]
Lapatinib + MK-4827 DCLVQU1 MK-4827 Adenocarcinoma (Cell Line: NCIH2122) [4]
Lapatinib + MK-4827 DCFKPCB MK-4827 Adenocarcinoma (Cell Line: NCIH23) [4]
Lapatinib + MK-4827 DC3IXI9 MK-4827 Adenocarcinoma (Cell Line: NCIH520) [4]
Lapatinib + MK-4827 DCX15U6 MK-4827 Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + MK-4827 DCKUVAX MK-4827 Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + MK-4827 DC2AQMJ MK-4827 Adenocarcinoma (Cell Line: HT29) [4]
Lapatinib + MK-4827 DCOWG8P MK-4827 Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + MK-4827 DC9OV8V MK-4827 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + MK-4827 DC6L7M8 MK-4827 Germ cell tumour (Cell Line: PA1) [4]
Lapatinib + MK-4827 DCCY7Y1 MK-4827 Malignant melanoma (Cell Line: A375) [4]
Lapatinib + MK-4827 DCSTLKF MK-4827 Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + MK-4827 DCN46IZ MK-4827 Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + MK-4827 DC73KQ8 MK-4827 Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + MK-4827 DCBSVGB MK-4827 Mesothelioma (Cell Line: MSTO) [4]
Lapatinib + MK-4827 DCU36L0 MK-4827 Non small cell carcinoma (Cell Line: SKMES1) [4]
Lapatinib + MK-4827 DCAAYO9 MK-4827 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + MK-4827 DCDMYZK MK-4827 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Lapatinib + Lomustine DC2KT12 Lomustine Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + Lomustine DCD3DHX Lomustine Mesothelioma (Cell Line: MSTO) [4]
Lapatinib + Lomustine DC6WTUA Lomustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + Bortezomib DCYCMC5 Bortezomib Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + Bortezomib DCUT0M0 Bortezomib Adenocarcinoma (Cell Line: A427) [4]
Lapatinib + Bortezomib DCAFJA7 Bortezomib Adenocarcinoma (Cell Line: NCIH2122) [4]
Lapatinib + Bortezomib DCXV6RZ Bortezomib Adenocarcinoma (Cell Line: NCIH23) [4]
Lapatinib + Bortezomib DCD4WHQ Bortezomib Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + Bortezomib DC9ZHJO Bortezomib Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + Bortezomib DCH6IMR Bortezomib Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + Bortezomib DC9XUBG Bortezomib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Lapatinib + Bortezomib DCV7GWY Bortezomib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + Bortezomib DCYYZKO Bortezomib Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + Bortezomib DC9C9OZ Bortezomib Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + Bortezomib DCHNND8 Bortezomib Non small cell carcinoma (Cell Line: SKMES1) [4]
Lapatinib + Bortezomib DCFIHVI Bortezomib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + Bortezomib DC7L6GU Bortezomib Prostate carcinoma (Cell Line: LNCAP) [4]
Lapatinib + Valrubicin DCYTO7X Valrubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Lapatinib + Valrubicin DCSLPLM Valrubicin Amelanotic melanoma (Cell Line: M14) [4]
Lapatinib + Valrubicin DCCZY1U Valrubicin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Lapatinib + Valrubicin DCP2ICM Valrubicin Glioma (Cell Line: SF-268) [4]
Lapatinib + Valrubicin DC7T0XN Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Lapatinib + Valrubicin DCAZ1XG Valrubicin Lung adenocarcinoma (Cell Line: EKVX) [4]
Lapatinib + Valrubicin DCCYP4F Valrubicin Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Lapatinib + GSK525762 DCO7KE5 GSK525762 Adenocarcinoma (Cell Line: NCIH1650) [4]
Lapatinib + GSK525762 DCNSVNL GSK525762 Germ cell tumour (Cell Line: PA1) [4]
Lapatinib + GSK525762 DCY0QUU GSK525762 Malignant melanoma (Cell Line: A375) [4]
Lapatinib + GSK525762 DCUE4Z7 GSK525762 Mesothelioma (Cell Line: MSTO) [4]
Lapatinib + GSK525762 DCI9Y9Z GSK525762 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + GSK525762 DCC5YCB GSK525762 Prostate carcinoma (Cell Line: LNCAP) [4]
Lapatinib + Cisplatin DCGF0M5 Cisplatin Melanoma (Cell Line: MALME-3M) [4]
Lapatinib + Chlorambucil DC3REP7 Chlorambucil Adenocarcinoma (Cell Line: DU-145) [4]
Lapatinib + Chlorambucil DCPB7SG Chlorambucil Amelanotic melanoma (Cell Line: M14) [4]
Lapatinib + Chlorambucil DC33JE6 Chlorambucil Glioma (Cell Line: SF-295) [4]
Lapatinib + Chlorambucil DCIEWFW Chlorambucil High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Lapatinib + Chlorambucil DCMNJS3 Chlorambucil High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Lapatinib + Chlorambucil DCYZ2NW Chlorambucil Lung adenocarcinoma (Cell Line: HOP-62) [4]
Lapatinib + Sorafenib DC4353L Sorafenib Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + Sorafenib DC3D362 Sorafenib Adenocarcinoma (Cell Line: OVCAR3) [4]
Lapatinib + Sorafenib DCKAO7M Sorafenib Adenocarcinoma (Cell Line: A427) [4]
Lapatinib + Sorafenib DCGZYEJ Sorafenib Adenocarcinoma (Cell Line: NCIH1650) [4]
Lapatinib + Sorafenib DC4L6GT Sorafenib Adenocarcinoma (Cell Line: NCIH2122) [4]
Lapatinib + Sorafenib DCR5ONT Sorafenib Adenocarcinoma (Cell Line: NCIH520) [4]
Lapatinib + Sorafenib DCE1EM8 Sorafenib Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + Sorafenib DCI0SUU Sorafenib Adenocarcinoma (Cell Line: HCT116) [4]
Lapatinib + Sorafenib DCHB97R Sorafenib Adenocarcinoma (Cell Line: SW-620) [4]
Lapatinib + Sorafenib DC9X8P0 Sorafenib Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + Sorafenib DC58RBZ Sorafenib Astrocytoma (Cell Line: U251) [4]
Lapatinib + Sorafenib DCY1YKF Sorafenib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Lapatinib + Sorafenib DCS5JKS Sorafenib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + Sorafenib DC07ROM Sorafenib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Lapatinib + Sorafenib DCAULY8 Sorafenib Malignant melanoma (Cell Line: A375) [4]
Lapatinib + Sorafenib DCQGBCJ Sorafenib Malignant melanoma (Cell Line: HT144) [4]
Lapatinib + Sorafenib DC37WZD Sorafenib Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + Sorafenib DCJMOEQ Sorafenib Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + Sorafenib DC0LPVS Sorafenib Mesothelioma (Cell Line: MSTO) [4]
Lapatinib + Sorafenib DCHOLN4 Sorafenib Non small cell carcinoma (Cell Line: SKMES1) [4]
Lapatinib + Sorafenib DCFLEC7 Sorafenib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + Sorafenib DCMH79C Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Lapatinib + Sorafenib DCU8GEC Sorafenib Prostate carcinoma (Cell Line: LNCAP) [4]
Lapatinib + Sorafenib DCU3US1 Sorafenib Prostate carcinoma (Cell Line: VCAP) [4]
Lapatinib + ER819762 DCLOH8Z ER819762 Adenocarcinoma (Cell Line: HCC-2998) [4]
Lapatinib + ER819762 DC3ESRO ER819762 Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Lapatinib + ER819762 DC7T8PX ER819762 Glioma (Cell Line: SF-268) [4]
Lapatinib + ER819762 DC7RJWB ER819762 Glioma (Cell Line: SF-295) [4]
Lapatinib + ER819762 DCVL6YC ER819762 Lung adenocarcinoma (Cell Line: HOP-62) [4]
Lapatinib + ER819762 DCKHH56 ER819762 Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Lapatinib + ER819762 DCXS7NZ ER819762 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Lapatinib + MK-2206 DC7QF2K MK-2206 Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + MK-2206 DCW5M62 MK-2206 Adenocarcinoma (Cell Line: OVCAR3) [4]
Lapatinib + MK-2206 DCP8ZUS MK-2206 Adenocarcinoma (Cell Line: NCIH1650) [4]
Lapatinib + MK-2206 DC9KE08 MK-2206 Adenocarcinoma (Cell Line: NCIH2122) [4]
Lapatinib + MK-2206 DC756UX MK-2206 Adenocarcinoma (Cell Line: NCIH23) [4]
Lapatinib + MK-2206 DC4DSH3 MK-2206 Adenocarcinoma (Cell Line: NCIH520) [4]
Lapatinib + MK-2206 DC8FGX3 MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + MK-2206 DC02DNR MK-2206 Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + MK-2206 DCBNHUK MK-2206 Adenocarcinoma (Cell Line: HCT116) [4]
Lapatinib + MK-2206 DC0RBBL MK-2206 Adenocarcinoma (Cell Line: HT29) [4]
Lapatinib + MK-2206 DCP6STQ MK-2206 Adenocarcinoma (Cell Line: SW-620) [4]
Lapatinib + MK-2206 DCXMDRK MK-2206 Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + MK-2206 DCJZG20 MK-2206 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + MK-2206 DC1P5B6 MK-2206 Germ cell tumour (Cell Line: PA1) [4]
Lapatinib + MK-2206 DC4CHS1 MK-2206 Malignant melanoma (Cell Line: A375) [4]
Lapatinib + MK-2206 DCJ3JUF MK-2206 Malignant melanoma (Cell Line: HT144) [4]
Lapatinib + MK-2206 DCHSPRB MK-2206 Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + MK-2206 DCEUHVI MK-2206 Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + MK-2206 DCR0WTW MK-2206 Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + MK-2206 DCAA2AP MK-2206 Mesothelioma (Cell Line: MSTO) [4]
Lapatinib + MK-2206 DCSMH6T MK-2206 Non small cell carcinoma (Cell Line: SKMES1) [4]
Lapatinib + MK-2206 DCAL8I7 MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + MK-2206 DCFB2IT MK-2206 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Lapatinib + MK-2206 DC5XC2V MK-2206 Prostate carcinoma (Cell Line: VCAP) [4]
Lapatinib + Pomalidomide DCUFEC4 Pomalidomide Adenocarcinoma (Cell Line: NCIH23) [4]
Lapatinib + Pomalidomide DC5RSJB Pomalidomide Adenocarcinoma (Cell Line: A549) [4]
Lapatinib + Pomalidomide DCK3WXV Pomalidomide Adenocarcinoma (Cell Line: HCT116) [4]
Lapatinib + Pomalidomide DCHS4T8 Pomalidomide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Lapatinib + Pomalidomide DCO62JX Pomalidomide Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + Vinflunine DCN5X64 Vinflunine Adenocarcinoma (Cell Line: HCT-15) [4]
Lapatinib + Vinflunine DC6SDWH Vinflunine Adenocarcinoma (Cell Line: HCC-2998) [4]
Lapatinib + Vinflunine DCHWWXX Vinflunine Astrocytoma (Cell Line: U251) [4]
Lapatinib + Vinflunine DCPQ4M8 Vinflunine Chronic myelogenous leukemia (Cell Line: K-562) [4]
Lapatinib + Vinflunine DCEXLU4 Vinflunine Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Lapatinib + Vinflunine DCST8LA Vinflunine Glioma (Cell Line: SF-539) [4]
Lapatinib + Vinflunine DCOCAX9 Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Lapatinib + Vinflunine DCDDUO0 Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Lapatinib + Vinflunine DCUS801 Vinflunine Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + Vinflunine DCW3415 Vinflunine Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Lapatinib + Vinflunine DC8OTR9 Vinflunine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lapatinib + Mepacrine DCJMECB Mepacrine Adenocarcinoma (Cell Line: OVCAR3) [4]
Lapatinib + PMID28870136-Compound-43 DCI9OK1 PMID28870136-Compound-43 Adenocarcinoma (Cell Line: HCT-15) [4]
Lapatinib + PMID28870136-Compound-43 DC4HN51 PMID28870136-Compound-43 Glioma (Cell Line: SF-268) [4]
Lapatinib + FORMESTANE DCBH5E1 FORMESTANE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Lapatinib + FORMESTANE DCFQ6Q9 FORMESTANE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Lapatinib + FORMESTANE DC06ESE FORMESTANE Lung adenocarcinoma (Cell Line: HOP-62) [4]
Lapatinib + FORMESTANE DCX1M57 FORMESTANE Melanoma (Cell Line: MALME-3M) [4]
Lapatinib + FORMESTANE DCD6CB8 FORMESTANE Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Lapatinib + Vorinostat DC1Q0F2 Vorinostat Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + Vorinostat DCJ0SXH Vorinostat Adenocarcinoma (Cell Line: A427) [4]
Lapatinib + Vorinostat DCZVJHA Vorinostat Adenocarcinoma (Cell Line: NCIH1650) [4]
Lapatinib + Vorinostat DCVHK2C Vorinostat Adenocarcinoma (Cell Line: NCIH2122) [4]
Lapatinib + Vorinostat DCJ78S8 Vorinostat Adenocarcinoma (Cell Line: NCIH23) [4]
Lapatinib + Vorinostat DCU3ID6 Vorinostat Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + Vorinostat DC1IGNI Vorinostat Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + Vorinostat DCGUPWN Vorinostat Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Lapatinib + Vorinostat DCRP7OQ Vorinostat Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Lapatinib + Vorinostat DC458L1 Vorinostat Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + Vorinostat DCYX2P1 Vorinostat Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + Vorinostat DC6CQ8P Vorinostat Non small cell carcinoma (Cell Line: SKMES1) [4]
Lapatinib + Vorinostat DCN3NXC Vorinostat Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + Vorinostat DCT8BQ2 Vorinostat Prostate carcinoma (Cell Line: VCAP) [4]
Lapatinib + Aminolevulinic Acid Hydrochloride DCRGVZS Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: DU-145) [4]
Lapatinib + Aminolevulinic Acid Hydrochloride DCXRLMR Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: OVCAR3) [4]
Lapatinib + Aminolevulinic Acid Hydrochloride DCQ4PUZ Aminolevulinic Acid Hydrochloride Astrocytoma (Cell Line: SNB-19) [4]
Lapatinib + Aminolevulinic Acid Hydrochloride DCGIJQ3 Aminolevulinic Acid Hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Lapatinib + Aminolevulinic Acid Hydrochloride DC92GRQ Aminolevulinic Acid Hydrochloride Malignant melanoma (Cell Line: LOX IMVI) [4]
Lapatinib + Busulfan DCDM9XR Busulfan Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Lapatinib + Busulfan DCZP2KR Busulfan Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Lapatinib + Dasatinib DCSKTZM Dasatinib Adenocarcinoma (Cell Line: CAOV3) [4]
Lapatinib + Dasatinib DCGGLRL Dasatinib Adenocarcinoma (Cell Line: A427) [4]
Lapatinib + Dasatinib DC7D1H4 Dasatinib Adenocarcinoma (Cell Line: NCIH520) [4]
Lapatinib + Dasatinib DCD4Q38 Dasatinib Adenocarcinoma (Cell Line: COLO320DM) [4]
Lapatinib + Dasatinib DCFHMFN Dasatinib Adenocarcinoma (Cell Line: DLD1) [4]
Lapatinib + Dasatinib DCACNCL Dasatinib Adenocarcinoma (Cell Line: HT29) [4]
Lapatinib + Dasatinib DCA4JT6 Dasatinib Adenocarcinoma (Cell Line: SW-620) [4]
Lapatinib + Dasatinib DCJ75EP Dasatinib Amelanotic melanoma (Cell Line: A2058) [4]
Lapatinib + Dasatinib DCW9ZKO Dasatinib Germ cell tumour (Cell Line: PA1) [4]
Lapatinib + Dasatinib DCW4F94 Dasatinib Malignant melanoma (Cell Line: RPMI7951) [4]
Lapatinib + Dasatinib DCFW8OO Dasatinib Malignant melanoma (Cell Line: SKMEL30) [4]
Lapatinib + Dasatinib DCZES1H Dasatinib Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + Dasatinib DCSV0CI Dasatinib Mesothelioma (Cell Line: MSTO) [4]
Lapatinib + Dasatinib DC5S8N4 Dasatinib Non small cell carcinoma (Cell Line: SKMES1) [4]
Lapatinib + Dasatinib DC2S6AT Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Lapatinib + Dasatinib DCDCM19 Dasatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Lapatinib + Dasatinib DCXYWK3 Dasatinib Prostate carcinoma (Cell Line: LNCAP) [4]
Lapatinib + Dasatinib DCTIN0Y Dasatinib Prostate carcinoma (Cell Line: VCAP) [4]
Lenalidomide + Lapatinib DCFGF3Z Lenalidomide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Lenalidomide + Lapatinib DCDWRWP Lenalidomide Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Lenalidomide + Lapatinib DCV9SF1 Lenalidomide Adenocarcinoma (Cell Line: A549) [4]
Lenalidomide + Lapatinib DCS7LLI Lenalidomide Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Lenalidomide + Lapatinib DCCWAIH Lenalidomide Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Lenalidomide + Lapatinib DCUBJF9 Lenalidomide Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Letrozole + Lapatinib DCB9N7U Letrozole Colon carcinoma (Cell Line: KM12) [3]
LIAROZOLE + Lapatinib DC6RTAY LIAROZOLE Astrocytoma (Cell Line: SNB-19) [5]
Mechlorethamine + Lapatinib DCFOTU7 Mechlorethamine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Mechlorethamine + Lapatinib DCXEZS4 Mechlorethamine Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Mechlorethamine + Lapatinib DC29HB8 Mechlorethamine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Metformin + Lapatinib DCF6E8R Metformin Adenocarcinoma (Cell Line: NCIH2122) [5]
Metformin + Lapatinib DCQJ959 Metformin Adenocarcinoma (Cell Line: SW-620) [5]
Metformin + Lapatinib DCP0YQP Metformin Germ cell tumour (Cell Line: PA1) [5]
Metformin + Lapatinib DCJ8FKK Metformin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Metformin + Lapatinib DCICXT3 Metformin Breast carcinoma (Cell Line: OCUBM) [3]
Methotrexate + Lapatinib DCWHNE1 Methotrexate Adenocarcinoma (Cell Line: NCIH23) [5]
Methotrexate + Lapatinib DCQT0RH Methotrexate Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Methotrexate + Lapatinib DCEHH9Q Methotrexate Malignant melanoma (Cell Line: UACC62) [5]
Methotrexate + Lapatinib DCODCV6 Methotrexate Prostate carcinoma (Cell Line: LNCAP) [5]
Methotrexate + Lapatinib DCWLR3W Methotrexate Colon adenocarcinoma (Cell Line: LOVO) [3]
Mitomycin + Lapatinib DC1RR9V Mitomycin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Mitomycin + Lapatinib DCZY3EK Mitomycin Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Mitomycin + Lapatinib DC2S0N8 Mitomycin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Mitomycin + Lapatinib DC4MJ2N Mitomycin Breast carcinoma (Cell Line: KPL1) [3]
Mitomycin + Lapatinib DCDSM28 Mitomycin Breast carcinoma (Cell Line: OCUBM) [3]
Mitomycin + Lapatinib DCCMRMZ Mitomycin Carcinoma (Cell Line: EFM192B) [3]
Mitomycin + Lapatinib DCR61I6 Mitomycin Colon adenocarcinoma (Cell Line: LOVO) [3]
Mitomycin + Lapatinib DCAO0MG Mitomycin Colon carcinoma (Cell Line: RKO) [3]
Mitomycin + Lapatinib DCA3I4L Mitomycin Invasive ductal carcinoma (Cell Line: T-47D) [3]
Mitomycin + Lapatinib DCVIRLG Mitomycin Rectal adenocarcinoma (Cell Line: SW837) [3]
Mitomycin + Lapatinib DCH1QKG Mitomycin Adenocarcinoma (Cell Line: CAOV3) [4]
Mitomycin + Lapatinib DCK0DIT Mitomycin Adenocarcinoma (Cell Line: A427) [4]
Mitomycin + Lapatinib DCDJP44 Mitomycin Adenocarcinoma (Cell Line: NCIH1650) [4]
Mitomycin + Lapatinib DC8CVU7 Mitomycin Adenocarcinoma (Cell Line: NCIH2122) [4]
Mitomycin + Lapatinib DCIXZ62 Mitomycin Adenocarcinoma (Cell Line: NCIH23) [4]
Mitomycin + Lapatinib DC0NAIU Mitomycin Adenocarcinoma (Cell Line: NCIH520) [4]
Mitomycin + Lapatinib DCE5MPO Mitomycin Adenocarcinoma (Cell Line: COLO320DM) [4]
Mitomycin + Lapatinib DCT57RP Mitomycin Adenocarcinoma (Cell Line: DLD1) [4]
Mitomycin + Lapatinib DC6LFUS Mitomycin Adenocarcinoma (Cell Line: HCT116) [4]
Mitomycin + Lapatinib DCZ3W8J Mitomycin Adenocarcinoma (Cell Line: HT29) [4]
Mitomycin + Lapatinib DCHLIM0 Mitomycin Amelanotic melanoma (Cell Line: A2058) [4]
Mitomycin + Lapatinib DCJOSTQ Mitomycin Malignant melanoma (Cell Line: RPMI7951) [4]
Mitomycin + Lapatinib DCZEEI2 Mitomycin Malignant melanoma (Cell Line: SKMEL30) [4]
Mitomycin + Lapatinib DC3PMPY Mitomycin Malignant melanoma (Cell Line: UACC62) [4]
Mitomycin + Lapatinib DCTGAG4 Mitomycin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Nilotinib + Lapatinib DCPSOPS Nilotinib Anaplastic large cell lymphoma (Cell Line: SR) [5]
Nilotinib + Lapatinib DCDFXBH Nilotinib Chronic myelogenous leukemia (Cell Line: K-562) [5]
PD-0325901 + Lapatinib DCERNQ6 PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
PD-0325901 + Lapatinib DCKKNGJ PD-0325901 Breast carcinoma (Cell Line: KPL1) [3]
PD-0325901 + Lapatinib DC2J4BT PD-0325901 Breast carcinoma (Cell Line: OCUBM) [3]
PD-0325901 + Lapatinib DCR6XGK PD-0325901 Carcinoma (Cell Line: EFM192B) [3]
PD-0325901 + Lapatinib DC6PCU2 PD-0325901 Carcinoma (Cell Line: MDAMB436) [3]
PD-0325901 + Lapatinib DCUI661 PD-0325901 Colon adenocarcinoma (Cell Line: LOVO) [3]
PD-0325901 + Lapatinib DCJRTDJ PD-0325901 Colon carcinoma (Cell Line: RKO) [3]
PD-0325901 + Lapatinib DCCB57U PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [3]
PD-0325901 + Lapatinib DCUY2HO PD-0325901 Rectal adenocarcinoma (Cell Line: SW837) [3]
PD-0325901 + Lapatinib DCXSDN6 PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [4]
PD-0325901 + Lapatinib DCXJO0W PD-0325901 Adenocarcinoma (Cell Line: A427) [4]
PD-0325901 + Lapatinib DCR78NF PD-0325901 Adenocarcinoma (Cell Line: NCIH1650) [4]
PD-0325901 + Lapatinib DCVT3VI PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [4]
PD-0325901 + Lapatinib DCOJZFW PD-0325901 Adenocarcinoma (Cell Line: NCIH23) [4]
PD-0325901 + Lapatinib DC0HN10 PD-0325901 Adenocarcinoma (Cell Line: NCIH520) [4]
PD-0325901 + Lapatinib DC94F7Y PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [4]
PD-0325901 + Lapatinib DCQQMQK PD-0325901 Adenocarcinoma (Cell Line: DLD1) [4]
PD-0325901 + Lapatinib DCLP8DL PD-0325901 Amelanotic melanoma (Cell Line: A2058) [4]
PD-0325901 + Lapatinib DCMASXK PD-0325901 Germ cell tumour (Cell Line: PA1) [4]
PD-0325901 + Lapatinib DCXY24W PD-0325901 Malignant melanoma (Cell Line: HT144) [4]
PD-0325901 + Lapatinib DCQH2CL PD-0325901 Malignant melanoma (Cell Line: RPMI7951) [4]
PD-0325901 + Lapatinib DC6XLIR PD-0325901 Malignant melanoma (Cell Line: SKMEL30) [4]
PD-0325901 + Lapatinib DCHTPI1 PD-0325901 Malignant melanoma (Cell Line: UACC62) [4]
PD-0325901 + Lapatinib DCN7XNQ PD-0325901 Mesothelioma (Cell Line: MSTO) [4]
PD-0325901 + Lapatinib DC7BUTH PD-0325901 Non small cell carcinoma (Cell Line: SKMES1) [4]
PD-0325901 + Lapatinib DCEJZX3 PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
PD-0325901 + Lapatinib DC1XLUB PD-0325901 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
PD-0325901 + Lapatinib DC51RDB PD-0325901 Prostate carcinoma (Cell Line: VCAP) [4]
Picoplatin + Lapatinib DCVXBTM Picoplatin Glioma (Cell Line: SF-268) [5]
Picoplatin + Lapatinib DCUBD3C Picoplatin Adenocarcinoma (Cell Line: NCIH23) [4]
Picoplatin + Lapatinib DCSP3XK Picoplatin Adenocarcinoma (Cell Line: HT29) [4]
Picoplatin + Lapatinib DCNQDVP Picoplatin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Picoplatin + Lapatinib DCDL04R Picoplatin Amelanotic melanoma (Cell Line: M14) [4]
Picoplatin + Lapatinib DCM72ID Picoplatin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Picoplatin + Lapatinib DC4CYLK Picoplatin Lung adenocarcinoma (Cell Line: HOP-62) [4]
PMID28460551-Compound-2 + Lapatinib DC9C9JI PMID28460551-Compound-2 Astrocytoma (Cell Line: SNB-19) [5]
PMID28460551-Compound-2 + Lapatinib DCOM4T1 PMID28460551-Compound-2 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
PMID28460551-Compound-2 + Lapatinib DCYNGJ7 PMID28460551-Compound-2 Renal cell carcinoma (Cell Line: SN12C) [5]
PMID28460551-Compound-2 + Lapatinib DCOJV0Z PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
PMID28460551-Compound-2 + Lapatinib DC7A4MJ PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
PMID28460551-Compound-2 + Lapatinib DCHEZJU PMID28460551-Compound-2 Breast carcinoma (Cell Line: ZR751) [3]
PMID28460551-Compound-2 + Lapatinib DCYZJ1K PMID28460551-Compound-2 Breast carcinoma (Cell Line: KPL1) [3]
PMID28460551-Compound-2 + Lapatinib DCC10LP PMID28460551-Compound-2 Breast carcinoma (Cell Line: OCUBM) [3]
PMID28460551-Compound-2 + Lapatinib DCNZ2NH PMID28460551-Compound-2 Carcinoma (Cell Line: OV90) [3]
PMID28460551-Compound-2 + Lapatinib DCTOBP7 PMID28460551-Compound-2 Carcinoma (Cell Line: EFM192B) [3]
PMID28460551-Compound-2 + Lapatinib DC974QV PMID28460551-Compound-2 Carcinoma (Cell Line: MDAMB436) [3]
PMID28460551-Compound-2 + Lapatinib DCEKR1K PMID28460551-Compound-2 Colon adenocarcinoma (Cell Line: LOVO) [3]
PMID28460551-Compound-2 + Lapatinib DC5IAPB PMID28460551-Compound-2 Colon carcinoma (Cell Line: RKO) [3]
PMID28460551-Compound-2 + Lapatinib DCQT9XT PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: HS 578T) [3]
PMID28460551-Compound-2 + Lapatinib DC2YJES PMID28460551-Compound-2 Rectal adenocarcinoma (Cell Line: SW837) [3]
PMID28460551-Compound-2 + Lapatinib DC48LEP PMID28460551-Compound-2 Adenocarcinoma (Cell Line: CAOV3) [4]
PMID28460551-Compound-2 + Lapatinib DC2WSKL PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH1650) [4]
PMID28460551-Compound-2 + Lapatinib DC1RX46 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH2122) [4]
PMID28460551-Compound-2 + Lapatinib DCTQTDU PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH23) [4]
PMID28460551-Compound-2 + Lapatinib DCYNBL8 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH520) [4]
PMID28460551-Compound-2 + Lapatinib DCOLF6Q PMID28460551-Compound-2 Adenocarcinoma (Cell Line: COLO320DM) [4]
PMID28460551-Compound-2 + Lapatinib DCOCOSS PMID28460551-Compound-2 Adenocarcinoma (Cell Line: DLD1) [4]
PMID28460551-Compound-2 + Lapatinib DCQRX2B PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HT29) [4]
PMID28460551-Compound-2 + Lapatinib DCCMJUN PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: A2058) [4]
PMID28460551-Compound-2 + Lapatinib DCUGMAD PMID28460551-Compound-2 Germ cell tumour (Cell Line: PA1) [4]
PMID28460551-Compound-2 + Lapatinib DC5LB93 PMID28460551-Compound-2 Malignant melanoma (Cell Line: RPMI7951) [4]
PMID28460551-Compound-2 + Lapatinib DCCHRV9 PMID28460551-Compound-2 Malignant melanoma (Cell Line: SKMEL30) [4]
PMID28460551-Compound-2 + Lapatinib DCU6VW2 PMID28460551-Compound-2 Malignant melanoma (Cell Line: UACC62) [4]
PMID28460551-Compound-2 + Lapatinib DCZALWS PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [4]
PMID28460551-Compound-2 + Lapatinib DCI9GSJ PMID28460551-Compound-2 Non small cell carcinoma (Cell Line: SKMES1) [4]
PMID28460551-Compound-2 + Lapatinib DCVUCST PMID28460551-Compound-2 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
PMID28460551-Compound-2 + Lapatinib DCBY00X PMID28460551-Compound-2 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
PMID28460551-Compound-2 + Lapatinib DCVGY0O PMID28460551-Compound-2 Prostate carcinoma (Cell Line: LNCAP) [4]
PMID28460551-Compound-2 + Lapatinib DCY3VA2 PMID28460551-Compound-2 Prostate carcinoma (Cell Line: VCAP) [4]
Raloxifene + Lapatinib DCP5VLZ Raloxifene Astrocytoma (Cell Line: U251) [5]
Raloxifene + Lapatinib DCY86KH Raloxifene Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Raloxifene + Lapatinib DCQTDSM Raloxifene Glioma (Cell Line: SF-268) [5]
Raloxifene + Lapatinib DCM1H40 Raloxifene Invasive ductal carcinoma (Cell Line: T-47D) [3]
Raloxifene + Lapatinib DCFYJ1D Raloxifene Adenocarcinoma (Cell Line: DU-145) [4]
Raloxifene + Lapatinib DCEG994 Raloxifene Adenocarcinoma (Cell Line: NCIH23) [4]
Raloxifene + Lapatinib DCK27DV Raloxifene Adenocarcinoma (Cell Line: HCC-2998) [4]
Raloxifene + Lapatinib DCAU1OG Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Raloxifene + Lapatinib DC0GOHU Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Raloxifene + Lapatinib DC36NLS Raloxifene Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Romidepsin + Lapatinib DCYWS1E Romidepsin Lung adenocarcinoma (Cell Line: EKVX) [4]
Ruxolitinib + Lapatinib DCHG466 Ruxolitinib Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Ruxolitinib + Lapatinib DCGN4GG Ruxolitinib Carcinoma (Cell Line: MCF7) [3]
Ruxolitinib + Lapatinib DCF8ZA0 Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Ruxolitinib + Lapatinib DC8F8M6 Ruxolitinib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Ruxolitinib + Lapatinib DC220Q6 Ruxolitinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Ruxolitinib + Lapatinib DCUW3PV Ruxolitinib Prostate carcinoma (Cell Line: PC-3) [4]
SCH 727965 + Lapatinib DCQRP13 SCH 727965 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
SCH 727965 + Lapatinib DCQLMYB SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
SCH 727965 + Lapatinib DC4T2R3 SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
SCH 727965 + Lapatinib DCM6MY8 SCH 727965 Breast carcinoma (Cell Line: KPL1) [3]
SCH 727965 + Lapatinib DCHMXVX SCH 727965 Breast carcinoma (Cell Line: OCUBM) [3]
SCH 727965 + Lapatinib DCBHIQZ SCH 727965 Carcinoma (Cell Line: OV90) [3]
SCH 727965 + Lapatinib DCRJQLH SCH 727965 Carcinoma (Cell Line: EFM192B) [3]
SCH 727965 + Lapatinib DCW8CRT SCH 727965 Carcinoma (Cell Line: MDAMB436) [3]
SCH 727965 + Lapatinib DC5WHWD SCH 727965 Colon adenocarcinoma (Cell Line: LOVO) [3]
SCH 727965 + Lapatinib DC8FPFW SCH 727965 Colon carcinoma (Cell Line: RKO) [3]
SCH 727965 + Lapatinib DCDP1Q8 SCH 727965 Invasive ductal carcinoma (Cell Line: T-47D) [3]
SCH 727965 + Lapatinib DCBIRCZ SCH 727965 Rectal adenocarcinoma (Cell Line: SW837) [3]
SCH 727965 + Lapatinib DCXT9GC SCH 727965 Adenocarcinoma (Cell Line: CAOV3) [4]
SCH 727965 + Lapatinib DCRBUTX SCH 727965 Adenocarcinoma (Cell Line: OVCAR3) [4]
SCH 727965 + Lapatinib DC13YSB SCH 727965 Adenocarcinoma (Cell Line: A427) [4]
SCH 727965 + Lapatinib DCL54WA SCH 727965 Adenocarcinoma (Cell Line: NCIH1650) [4]
SCH 727965 + Lapatinib DCV3M1I SCH 727965 Adenocarcinoma (Cell Line: NCIH2122) [4]
SCH 727965 + Lapatinib DCLPPZ0 SCH 727965 Adenocarcinoma (Cell Line: NCIH23) [4]
SCH 727965 + Lapatinib DCXNBQ0 SCH 727965 Adenocarcinoma (Cell Line: NCIH520) [4]
SCH 727965 + Lapatinib DC8NREV SCH 727965 Adenocarcinoma (Cell Line: COLO320DM) [4]
SCH 727965 + Lapatinib DCAXXR2 SCH 727965 Adenocarcinoma (Cell Line: DLD1) [4]
SCH 727965 + Lapatinib DCQMHPI SCH 727965 Adenocarcinoma (Cell Line: HCT116) [4]
SCH 727965 + Lapatinib DCG6KRX SCH 727965 Adenocarcinoma (Cell Line: HT29) [4]
SCH 727965 + Lapatinib DCN9MKR SCH 727965 Amelanotic melanoma (Cell Line: A2058) [4]
SCH 727965 + Lapatinib DC0F3DB SCH 727965 Germ cell tumour (Cell Line: PA1) [4]
SCH 727965 + Lapatinib DCGEUEJ SCH 727965 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
SCH 727965 + Lapatinib DCRN70O SCH 727965 Malignant melanoma (Cell Line: HT144) [4]
SCH 727965 + Lapatinib DCCR44N SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [4]
SCH 727965 + Lapatinib DCMRUVM SCH 727965 Malignant melanoma (Cell Line: SKMEL30) [4]
SCH 727965 + Lapatinib DCBK6ZT SCH 727965 Malignant melanoma (Cell Line: UACC62) [4]
SCH 727965 + Lapatinib DCUR672 SCH 727965 Mesothelioma (Cell Line: MSTO) [4]
SCH 727965 + Lapatinib DC12UZ6 SCH 727965 Non small cell carcinoma (Cell Line: SKMES1) [4]
SCH 727965 + Lapatinib DC2CN77 SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
SCH 727965 + Lapatinib DCMEIY5 SCH 727965 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
SCH 727965 + Lapatinib DC02XQC SCH 727965 Prostate carcinoma (Cell Line: VCAP) [4]
Sirolimus + Lapatinib DCCMSKL Sirolimus Anaplastic large cell lymphoma (Cell Line: SR) [5]
Sirolimus + Lapatinib DCX6X2A Sirolimus Astrocytoma (Cell Line: SNB-19) [5]
Sirolimus + Lapatinib DC81Q64 Sirolimus Chronic myelogenous leukemia (Cell Line: K-562) [5]
Sirolimus + Lapatinib DC8DFRJ Sirolimus Clear cell renal cell carcinoma (Cell Line: A498) [5]
Sirolimus + Lapatinib DCKVHNO Sirolimus Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Sirolimus + Lapatinib DCC5VXQ Sirolimus Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Sirolimus + Lapatinib DCHH364 Sirolimus Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Sirolimus + Lapatinib DCXOLH6 Sirolimus Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Sirolimus + Lapatinib DC9AMY8 Sirolimus Renal cell carcinoma (Cell Line: UO-31) [5]
Sirolimus + Lapatinib DCUR8MW Sirolimus Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Sirolimus + Lapatinib DCMO56E Sirolimus Colon adenocarcinoma (Cell Line: COLO 205) [3]
Sirolimus + Lapatinib DCDD7CT Sirolimus Colon carcinoma (Cell Line: KM12) [3]
Sirolimus + Lapatinib DCWZ6D1 Sirolimus Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Sirolimus + Lapatinib DC0KKYA Sirolimus Invasive ductal carcinoma (Cell Line: BT-549) [3]
Sirolimus + Lapatinib DCU1ARS Sirolimus Adenocarcinoma (Cell Line: DU-145) [4]
Sirolimus + Lapatinib DCVR78D Sirolimus Adenocarcinoma (Cell Line: OVCAR3) [4]
Sirolimus + Lapatinib DCQPO9W Sirolimus Adenocarcinoma (Cell Line: NCIH23) [4]
Sirolimus + Lapatinib DC2T1AX Sirolimus Adenocarcinoma (Cell Line: A549) [4]
Sirolimus + Lapatinib DC8LNN6 Sirolimus Adenocarcinoma (Cell Line: SW-620) [4]
Sirolimus + Lapatinib DCS4QIF Sirolimus Adenocarcinoma (Cell Line: HCC-2998) [4]
Sirolimus + Lapatinib DCVYQDD Sirolimus Adenocarcinoma (Cell Line: HCT-15) [4]
Sirolimus + Lapatinib DC3ONFW Sirolimus Adenocarcinoma (Cell Line: HCT116) [4]
Sirolimus + Lapatinib DCS8OSN Sirolimus Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Sirolimus + Lapatinib DCA0IKM Sirolimus Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Sirolimus + Lapatinib DCLV9UI Sirolimus Lung adenocarcinoma (Cell Line: EKVX) [4]
Sirolimus + Lapatinib DC32URJ Sirolimus Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Sirolimus + Lapatinib DCPHZ5A Sirolimus Prostate carcinoma (Cell Line: PC-3) [4]
SY-1425 + Lapatinib DC5ZACX SY-1425 Adenocarcinoma (Cell Line: HCT116) [4]
Taxol + Lapatinib DCFAQVG Taxol Anaplastic large cell lymphoma (Cell Line: SR) [5]
Taxol + Lapatinib DCV0Q5W Taxol Clear cell renal cell carcinoma (Cell Line: A498) [5]
Taxol + Lapatinib DC44E08 Taxol Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Taxol + Lapatinib DCNGZEB Taxol Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Taxol + Lapatinib DC5MN3U Taxol Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Taxol + Lapatinib DCX0X37 Taxol Glioblastoma (Cell Line: SNB-75) [5]
Taxol + Lapatinib DCFPA2G Taxol Glioma (Cell Line: SF-295) [5]
Taxol + Lapatinib DC20JTY Taxol Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Taxol + Lapatinib DCDM6OT Taxol Renal cell carcinoma (Cell Line: UO-31) [5]
Taxol + Lapatinib DCDCVOV Taxol Renal cell carcinoma (Cell Line: SN12C) [5]
Taxol + Lapatinib DC2SZTT Taxol Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Taxol + Lapatinib DC4BBTZ Taxol Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Taxol + Lapatinib DCXHDLC Taxol Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Taxol + Lapatinib DCDKRWE Taxol Breast carcinoma (Cell Line: OCUBM) [3]
Taxol + Lapatinib DCBU22M Taxol Carcinoma (Cell Line: MDAMB436) [3]
Taxol + Lapatinib DCSARDK Taxol Carcinoma (Cell Line: MCF7) [3]
Taxol + Lapatinib DCVPTT3 Taxol Colon adenocarcinoma (Cell Line: LOVO) [3]
Taxol + Lapatinib DCRYGIP Taxol Colon carcinoma (Cell Line: KM12) [3]
Taxol + Lapatinib DCNNDOA Taxol Invasive ductal carcinoma (Cell Line: T-47D) [3]
Taxol + Lapatinib DCN7F6I Taxol Rectal adenocarcinoma (Cell Line: SW837) [3]
Taxol + Lapatinib DCK6Z93 Taxol Adenocarcinoma (Cell Line: DU-145) [4]
Taxol + Lapatinib DC7WQGF Taxol Adenocarcinoma (Cell Line: CAOV3) [4]
Taxol + Lapatinib DCYHE5D Taxol Adenocarcinoma (Cell Line: OVCAR3) [4]
Taxol + Lapatinib DCT36VT Taxol Adenocarcinoma (Cell Line: A549) [4]
Taxol + Lapatinib DC61E9U Taxol Adenocarcinoma (Cell Line: NCIH23) [4]
Taxol + Lapatinib DCL01S3 Taxol Adenocarcinoma (Cell Line: COLO320DM) [4]
Taxol + Lapatinib DCN27YH Taxol Adenocarcinoma (Cell Line: DLD1) [4]
Taxol + Lapatinib DC3HLC1 Taxol Amelanotic melanoma (Cell Line: A2058) [4]
Taxol + Lapatinib DCEC35A Taxol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Taxol + Lapatinib DCPYKCL Taxol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Taxol + Lapatinib DCJI5XI Taxol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Taxol + Lapatinib DCO2RJ6 Taxol High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Taxol + Lapatinib DCKOL9M Taxol Lung adenocarcinoma (Cell Line: EKVX) [4]
Taxol + Lapatinib DCXSRCN Taxol Lung adenocarcinoma (Cell Line: HOP-62) [4]
Taxol + Lapatinib DC034D1 Taxol Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Taxol + Lapatinib DCYD78S Taxol Malignant melanoma (Cell Line: HT144) [4]
Taxol + Lapatinib DCDAM0L Taxol Malignant melanoma (Cell Line: RPMI7951) [4]
Taxol + Lapatinib DCGWUSA Taxol Malignant melanoma (Cell Line: SKMEL30) [4]
Taxol + Lapatinib DCJ75O1 Taxol Malignant melanoma (Cell Line: UACC62) [4]
Taxol + Lapatinib DCU9IPI Taxol Melanoma (Cell Line: UACC-257) [4]
Taxol + Lapatinib DCUNO9J Taxol Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Taxol + Lapatinib DCGP6NU Taxol Non small cell carcinoma (Cell Line: SKMES1) [4]
Taxol + Lapatinib DCPRU66 Taxol Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Taxol + Lapatinib DCI4O4J Taxol Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Taxol + Lapatinib DCL5X5I Taxol Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Taxol + Lapatinib DCD8P7I Taxol Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Taxol + Lapatinib DCFIFV7 Taxol Prostate carcinoma (Cell Line: PC-3) [4]
Thioguanine + Lapatinib DCUNJG8 Thioguanine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Thioguanine + Lapatinib DC2DDDL Thioguanine Anaplastic large cell lymphoma (Cell Line: SR) [5]
Thioguanine + Lapatinib DCMOM38 Thioguanine Astrocytoma (Cell Line: U251) [5]
Thioguanine + Lapatinib DCEDA4O Thioguanine Astrocytoma (Cell Line: SNB-19) [5]
Thioguanine + Lapatinib DCJIZFX Thioguanine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Thioguanine + Lapatinib DC578HS Thioguanine Glioma (Cell Line: SF-539) [5]
Thioguanine + Lapatinib DC8EFUE Thioguanine Glioma (Cell Line: SF-295) [5]
Thioguanine + Lapatinib DCYJFHG Thioguanine Carcinoma (Cell Line: MCF7) [3]
Thioguanine + Lapatinib DCHQDQ5 Thioguanine Colon adenocarcinoma (Cell Line: COLO 205) [3]
Thioguanine + Lapatinib DCBLBID Thioguanine Adenocarcinoma (Cell Line: DU-145) [4]
Thioguanine + Lapatinib DCQ1T2U Thioguanine Adenocarcinoma (Cell Line: A549) [4]
Thioguanine + Lapatinib DCNW6AW Thioguanine Adenocarcinoma (Cell Line: NCIH23) [4]
Thioguanine + Lapatinib DCUZ7B5 Thioguanine Adenocarcinoma (Cell Line: HT29) [4]
Thioguanine + Lapatinib DC1YRNF Thioguanine Adenocarcinoma (Cell Line: HCT116) [4]
Thioguanine + Lapatinib DC4YFOI Thioguanine Amelanotic melanoma (Cell Line: M14) [4]
Thioguanine + Lapatinib DC400VD Thioguanine Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Thioguanine + Lapatinib DCXW1QY Thioguanine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Thioguanine + Lapatinib DCJX6EX Thioguanine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Thioguanine + Lapatinib DC1W0WQ Thioguanine Malignant melanoma (Cell Line: UACC62) [4]
Thioguanine + Lapatinib DC1LKWS Thioguanine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Topotecan + Lapatinib DC2PFRZ Topotecan Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Topotecan + Lapatinib DCRZL02 Topotecan Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Topotecan + Lapatinib DCXVPTH Topotecan Carcinoma (Cell Line: MDAMB436) [3]
Topotecan + Lapatinib DCHTJVO Topotecan Carcinoma (Cell Line: MCF7) [3]
Topotecan + Lapatinib DC5IYT7 Topotecan Colon adenocarcinoma (Cell Line: LOVO) [3]
Topotecan + Lapatinib DCHYCI4 Topotecan Colon carcinoma (Cell Line: RKO) [3]
Topotecan + Lapatinib DCQ3W5L Topotecan Adenocarcinoma (Cell Line: CAOV3) [4]
Topotecan + Lapatinib DCJPHFZ Topotecan Adenocarcinoma (Cell Line: A427) [4]
Topotecan + Lapatinib DCQVINH Topotecan Adenocarcinoma (Cell Line: NCIH2122) [4]
Topotecan + Lapatinib DCS485X Topotecan Adenocarcinoma (Cell Line: A549) [4]
Topotecan + Lapatinib DCGB6G4 Topotecan Adenocarcinoma (Cell Line: COLO320DM) [4]
Topotecan + Lapatinib DCLJRLI Topotecan Adenocarcinoma (Cell Line: DLD1) [4]
Topotecan + Lapatinib DCXVRJC Topotecan Adenocarcinoma (Cell Line: HCT116) [4]
Topotecan + Lapatinib DC8X9XO Topotecan Adenocarcinoma (Cell Line: HT29) [4]
Topotecan + Lapatinib DCT6ZP7 Topotecan Amelanotic melanoma (Cell Line: A2058) [4]
Topotecan + Lapatinib DCCHMAX Topotecan Astrocytoma (Cell Line: SNB-19) [4]
Topotecan + Lapatinib DC7EZMP Topotecan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Topotecan + Lapatinib DCVUTTJ Topotecan Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Topotecan + Lapatinib DCUCO7M Topotecan Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Topotecan + Lapatinib DC6DQRB Topotecan Germ cell tumour (Cell Line: PA1) [4]
Topotecan + Lapatinib DCJQZTD Topotecan Glioma (Cell Line: SF-268) [4]
Topotecan + Lapatinib DC1O210 Topotecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Topotecan + Lapatinib DCYOPYQ Topotecan Malignant melanoma (Cell Line: RPMI7951) [4]
Topotecan + Lapatinib DCEGB43 Topotecan Malignant melanoma (Cell Line: SKMEL30) [4]
Topotecan + Lapatinib DCJ7NF1 Topotecan Malignant melanoma (Cell Line: UACC62) [4]
Topotecan + Lapatinib DCYI29S Topotecan Melanoma (Cell Line: MALME-3M) [4]
Topotecan + Lapatinib DCGJXJA Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Topotecan + Lapatinib DCBEKBF Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Topotecan + Lapatinib DC4MBOD Topotecan Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Topotecan + Lapatinib DCXH2KT Topotecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Topotecan + Lapatinib DCL5U9T Topotecan Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Topotecan + Lapatinib DCMQJ51 Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Topotecan + Lapatinib DCQPSNL Topotecan Prostate carcinoma (Cell Line: VCAP) [4]
Topotecan + Lapatinib DCQS5F5 Topotecan Prostate carcinoma (Cell Line: PC-3) [4]
Trifluridine + Lapatinib DCEZ8HA Trifluridine Adenocarcinoma (Cell Line: NCIH23) [4]
Trifluridine + Lapatinib DCUD2AQ Trifluridine Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Trifluridine + Lapatinib DCGCSIS Trifluridine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Trifluridine + Lapatinib DC88WBS Trifluridine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Uracil mustard + Lapatinib DCLDPII Uracil mustard Anaplastic large cell lymphoma (Cell Line: SR) [5]
Uracil mustard + Lapatinib DCQ01OJ Uracil mustard Astrocytoma (Cell Line: SNB-19) [5]
Uracil mustard + Lapatinib DC4UM7Y Uracil mustard Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Uracil mustard + Lapatinib DC8DKVH Uracil mustard Adenocarcinoma (Cell Line: DU-145) [4]
Uracil mustard + Lapatinib DC1GCYU Uracil mustard Adenocarcinoma (Cell Line: A549) [4]
Uracil mustard + Lapatinib DCH99M6 Uracil mustard Adenocarcinoma (Cell Line: HCT-15) [4]
Uracil mustard + Lapatinib DCKHEBU Uracil mustard Lung adenocarcinoma (Cell Line: EKVX) [4]
Vandetanib + Lapatinib DC4T004 Vandetanib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Lapatinib DCTHGJS Vandetanib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vandetanib + Lapatinib DCJU5LU Vandetanib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vemurafenib + Lapatinib DC27MQY Vemurafenib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vemurafenib + Lapatinib DCK0GUN Vemurafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vemurafenib + Lapatinib DCMO8LK Vemurafenib Glioma (Cell Line: SF-539) [4]
Vemurafenib + Lapatinib DCP3S4G Vemurafenib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vemurafenib + Lapatinib DCBS3JP Vemurafenib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vemurafenib + Lapatinib DCK9QOB Vemurafenib Melanoma (Cell Line: SK-MEL-2) [4]
Vemurafenib + Lapatinib DCGY1B4 Vemurafenib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vemurafenib + Lapatinib DC3OUF7 Vemurafenib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vemurafenib + Lapatinib DC6IFAS Vemurafenib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vemurafenib + Lapatinib DCFUSYW Vemurafenib Prostate carcinoma (Cell Line: PC-3) [4]
Vinblastine + Lapatinib DCLJZO7 Vinblastine Adenocarcinoma (Cell Line: CAOV3) [5]
Vinblastine + Lapatinib DCUE4LH Vinblastine Adenocarcinoma (Cell Line: NCIH2122) [5]
Vinblastine + Lapatinib DCKF985 Vinblastine Adenocarcinoma (Cell Line: NCIH23) [5]
Vinblastine + Lapatinib DCWQDGU Vinblastine Adenocarcinoma (Cell Line: COLO320DM) [5]
Vinblastine + Lapatinib DC5JFX6 Vinblastine Adenocarcinoma (Cell Line: DLD1) [5]
Vinblastine + Lapatinib DC9PHQO Vinblastine Amelanotic melanoma (Cell Line: A2058) [5]
Vinblastine + Lapatinib DCKQTB3 Vinblastine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Vinblastine + Lapatinib DCPIKUP Vinblastine Malignant melanoma (Cell Line: RPMI7951) [5]
Vinblastine + Lapatinib DCVDV8K Vinblastine Malignant melanoma (Cell Line: SKMEL30) [5]
Vinblastine + Lapatinib DCL4NTC Vinblastine Malignant melanoma (Cell Line: UACC62) [5]
Vinblastine + Lapatinib DCX5WYO Vinblastine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Vinblastine + Lapatinib DCYLRUU Vinblastine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vinblastine + Lapatinib DC4EWUY Vinblastine Prostate carcinoma (Cell Line: VCAP) [5]
Vinblastine + Lapatinib DC1H99O Vinblastine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Vinblastine + Lapatinib DCNYV13 Vinblastine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Vinblastine + Lapatinib DC93T4L Vinblastine Breast carcinoma (Cell Line: KPL1) [3]
Vinblastine + Lapatinib DC87NOS Vinblastine Breast carcinoma (Cell Line: OCUBM) [3]
Vinblastine + Lapatinib DCX6XU7 Vinblastine Rectal adenocarcinoma (Cell Line: SW837) [3]
Vincristine + Lapatinib DC3CSL3 Vincristine Adenocarcinoma (Cell Line: DU-145) [5]
Vincristine + Lapatinib DCS6AOK Vincristine Adenocarcinoma (Cell Line: OVCAR3) [5]
Vincristine + Lapatinib DC2CW35 Vincristine Adenocarcinoma (Cell Line: A549) [5]
Vincristine + Lapatinib DC7F25A Vincristine Adenocarcinoma (Cell Line: HT29) [5]
Vincristine + Lapatinib DC9E34Q Vincristine Adenocarcinoma (Cell Line: HCT-15) [5]
Vincristine + Lapatinib DCAXEWF Vincristine Adenocarcinoma (Cell Line: HCT116) [5]
Vincristine + Lapatinib DC7SW5S Vincristine Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vincristine + Lapatinib DCFX50Q Vincristine Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vincristine + Lapatinib DCV4YT8 Vincristine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vincristine + Lapatinib DCFVIES Vincristine Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vincristine + Lapatinib DCWICSW Vincristine Glioma (Cell Line: SF-268) [5]
Vincristine + Lapatinib DC0FN9T Vincristine Glioma (Cell Line: SF-295) [5]
Vincristine + Lapatinib DCYF3AJ Vincristine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Vincristine + Lapatinib DC63BGT Vincristine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vincristine + Lapatinib DCLQ3GA Vincristine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Vincristine + Lapatinib DC1YV4Y Vincristine Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vincristine + Lapatinib DCMWEFA Vincristine Lung adenocarcinoma (Cell Line: EKVX) [5]
Vincristine + Lapatinib DC7EVSN Vincristine Melanoma (Cell Line: UACC-257) [5]
Vincristine + Lapatinib DCD56FH Vincristine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vincristine + Lapatinib DCKPCHI Vincristine Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vincristine + Lapatinib DCO5VI5 Vincristine Prostate carcinoma (Cell Line: PC-3) [5]
Vincristine + Lapatinib DCRQUU8 Vincristine Renal cell carcinoma (Cell Line: SN12C) [5]
Vincristine + Lapatinib DCSJ0U9 Vincristine Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vincristine + Lapatinib DC7AJIN Vincristine Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vincristine + Lapatinib DC2OUYJ Vincristine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vinorelbine + Lapatinib DCVFV0B Vinorelbine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [3]
Vinorelbine + Lapatinib DC3WWW9 Vinorelbine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [3]
Vinorelbine + Lapatinib DCBRMXP Vinorelbine Breast carcinoma (Cell Line: KPL1) [3]
Vinorelbine + Lapatinib DCZT9Y7 Vinorelbine Breast carcinoma (Cell Line: OCUBM) [3]
Vinorelbine + Lapatinib DC7ZA8X Vinorelbine Carcinoma (Cell Line: EFM192B) [3]
Vinorelbine + Lapatinib DCIIS61 Vinorelbine Colon adenocarcinoma (Cell Line: LOVO) [3]
Vinorelbine + Lapatinib DCYY5WT Vinorelbine Adenocarcinoma (Cell Line: CAOV3) [4]
Vinorelbine + Lapatinib DCUSXHB Vinorelbine Adenocarcinoma (Cell Line: NCIH2122) [4]
Vinorelbine + Lapatinib DC7828V Vinorelbine Adenocarcinoma (Cell Line: NCIH520) [4]
Vinorelbine + Lapatinib DCRB3JB Vinorelbine Adenocarcinoma (Cell Line: COLO320DM) [4]
Vinorelbine + Lapatinib DCIKW7T Vinorelbine Adenocarcinoma (Cell Line: DLD1) [4]
Vinorelbine + Lapatinib DCYY3HD Vinorelbine Adenocarcinoma (Cell Line: HCT116) [4]
Vinorelbine + Lapatinib DCAUFJC Vinorelbine Amelanotic melanoma (Cell Line: A2058) [4]
Vinorelbine + Lapatinib DCJXB51 Vinorelbine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Vinorelbine + Lapatinib DCO56IC Vinorelbine Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vinorelbine + Lapatinib DCUWRSU Vinorelbine Malignant melanoma (Cell Line: HT144) [4]
Vinorelbine + Lapatinib DC2978F Vinorelbine Malignant melanoma (Cell Line: RPMI7951) [4]
Vinorelbine + Lapatinib DC96ESD Vinorelbine Malignant melanoma (Cell Line: SKMEL30) [4]
Vinorelbine + Lapatinib DCWIPFJ Vinorelbine Malignant melanoma (Cell Line: UACC62) [4]
Vinorelbine + Lapatinib DC52WPT Vinorelbine Non small cell carcinoma (Cell Line: SKMES1) [4]
Vinorelbine + Lapatinib DCP8BDX Vinorelbine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Vinorelbine + Lapatinib DCCL93F Vinorelbine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Vismodegib + Lapatinib DC6W87Q Vismodegib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vismodegib + Lapatinib DCVAP2O Vismodegib Carcinoma (Cell Line: MCF7) [3]
Vismodegib + Lapatinib DCSMHFG Vismodegib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vismodegib + Lapatinib DCDW7MC Vismodegib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vismodegib + Lapatinib DCVRLZX Vismodegib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vismodegib + Lapatinib DCA1HDW Vismodegib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vismodegib + Lapatinib DCWC5KI Vismodegib Malignant melanoma (Cell Line: UACC62) [4]
Vismodegib + Lapatinib DC7EYTQ Vismodegib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 1316 DrugCom(s)
29 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Lapatinib + Docetaxel DC39K68 Docetaxel Neoplasms, Breast [6]
Lapatinib + Gemcitabine DC8TZKW Gemcitabine Metastatic Pancreatic Cancer [7]
Lapatinib + Panobinostat DCBG7QK Panobinostat Breast Cancer [8]
Lapatinib + Metformin DC19AY7 Metformin Advanced Cancers [9]
Lapatinib + Digoxin DC1JKPH Digoxin Neoplasms, Breast [10]
Lapatinib + Docetaxel DC3OMTZ Docetaxel Neoplasms, Breast [11]
Lapatinib + Topotecan DC6UAXV Topotecan Ovarian Cancer [12]
Lapatinib + Temozolomide DC73YZZ Temozolomide Brain Tumors [13]
Lapatinib + XL880 DCAHJZ9 XL880 Breast Cancer [14]
Lapatinib + Vinorelbine DCAUQG4 Vinorelbine Breast Cancer [15]
Lapatinib + Vorinostat DCBGJ59 Vorinostat Breast Cancer [16]
Lapatinib + Capecitabine DCEJ7BH Capecitabine Breast Cancer [17]
Lapatinib + Valproic Acid DCGINTW Valproic Acid Solid Tumors [18]
Lapatinib + Letrozole DCHGDDP Letrozole Neoplasms, Breast [19]
Lapatinib + Pemetrexed DCHUIOX Pemetrexed Lung Cancer, Non-Small Cell [20]
Lapatinib + Panobinostat DCIZGA3 Panobinostat Breast Cancer [8]
Lapatinib + Letrozole DCKK4B7 Letrozole Breast Neoplasms [21]
Lapatinib + Midazolam DCMTEK5 Midazolam Neoplasms, Breast [22]
Lapatinib + Pazopanib DCR384Z Pazopanib Carcinoma, Renal Cell [23]
Lapatinib + Gemcitabine DCSWME9 Gemcitabine Metastatic Pancreatic Cancer [7]
Lapatinib + Exemestane DCZA7XF Exemestane Breast Cancer [24]
Lapatinib + Oxaliplatin DC59A3V Oxaliplatin Neoplasms, Colorectal [25]
Trametinib + Lapatinib DCOAJVZ Trametinib Colorectal Cancer [26]
Lapatinib + Cyclophosphamide DCJVI8F Cyclophosphamide Breast Cancer [27]
Lapatinib + Octreotide DC06496 Octreotide Cancer [28]
Lapatinib + Everolimus DCXJ6ZK Everolimus Breast Neoplasms [29]
Lapatinib + Cabazitaxel DCHO9NG Cabazitaxel Metastatic Breast Cancer With Intracranial Metastases [30]
Fulvestrant + Lapatinib DC6BPFP Fulvestrant Metastatic Breast Cancer [31]
Lapatinib + Oxaliplatin DCY85TZ Oxaliplatin Neoplasms, Gastrointestinal Tract [32]
------------------------------------------------------------------------------------
⏷ Show the Full List of 29 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5692).
2 Lapatinib FDA Label
3 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
4 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
5 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6 ClinicalTrials.gov (NCT00388076) Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
7 ClinicalTrials.gov (NCT00447122) BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
8 ClinicalTrials.gov (NCT00632489) LBH589 in Combination With Capecitabine Plus/Minus () Lapatinib in Breast Cancer Patients
9 ClinicalTrials.gov (NCT01087983) Lapatinib With Sirolimus or Metformin
10 ClinicalTrials.gov (NCT00650910) Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer
11 ClinicalTrials.gov (NCT00148902) Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
12 ClinicalTrials.gov (NCT00436644) Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
13 ClinicalTrials.gov (NCT00826241) Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
14 ClinicalTrials.gov (NCT01138384) Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer
15 ClinicalTrials.gov (NCT00513058) Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer
16 ClinicalTrials.gov (NCT01118975) GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
17 ClinicalTrials.gov (NCT00078572) Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer
18 ClinicalTrials.gov (NCT00495872) Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
19 ClinicalTrials.gov (NCT00422903) Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
20 ClinicalTrials.gov (NCT00528281) A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase
21 ClinicalTrials.gov (NCT00073528) Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer
22 ClinicalTrials.gov (NCT00258050) To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
23 ClinicalTrials.gov (NCT00158782) Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
24 ClinicalTrials.gov (NCT01005641) ELBA: Exemestane and Lapatinib in Advanced Breast Cancer
25 ClinicalTrials.gov (NCT00536809) Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
26 ClinicalTrials.gov (NCT02230553) Lapatinib Plus Trametinib in KRAS Mutant NSCLC
27 ClinicalTrials.gov (NCT00841828) Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
28 ClinicalTrials.gov (NCT02294786) Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
29 ClinicalTrials.gov (NCT01499160) Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
30 ClinicalTrials.gov (NCT01934894) Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
31 ClinicalTrials.gov (NCT02394496) Overcoming Endocrine Resistance in Metastatic Breast Cancer
32 ClinicalTrials.gov (NCT00680901) LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib